

ANNUAL STATEMENT

OF THE

BLUE CROSS & BLUE SHIELD OF RHODE ISLAND

of PROVIDENCE COUNTY
STATE OF RHODE ISLAND

TO THE

Insurance Department

OF THE

STATE OF RHODE ISLAND

FOR THE YEAR ENDED

December 31, 2024

HEALTH

2024



53473202420100100

ANNUAL STATEMENT

For the Year Ended December 31, 2024
OF THE CONDITION AND AFFAIRS OF THE

BLUE CROSS & BLUE SHIELD OF RHODE ISLAND

NAIC Group Code	0000	0000	NAIC Company Code	53473	Employer's ID Number	05-0158952
	(Current Period)	(Prior Period)				
Organized under the Laws of	RHODE ISLAND			, State of Domicile or Port of Entry		
Country of Domicile	USA					
Licensed as business type:	Life, Accident & Health	[]	Property/Casualty	[]	Hospital, Medical & Dental Service or Indemnity	[X]
	Dental Service Corporation	[]	Vision Service Corporation	[]	Health Maintenance Organization	[]
	Other	[]	Is HMO Federally Qualified?	Yes [] No []		
Incorporated/Organized	February 27, 1939			Commenced Business		
Statutory Home Office	500 EXCHANGE STREET			PROVIDENCE, RI, US 02903		
	(Street and Number)			(City or Town, State, Country and Zip Code)		
Main Administrative Office	500 EXCHANGE STREET					
	(Street and Number)					
	PROVIDENCE, RI, US 02903			401-459-1000		
	(City or Town, State, Country and Zip Code)			(Area Code) (Telephone Number)		
Mail Address	500 EXCHANGE STREET			PROVIDENCE, RI, US 02903		
	(Street and Number or P.O. Box)			(City or Town, State, Country and Zip Code)		
Primary Location of Books and Records	500 EXCHANGE STREET			PROVIDENCE, RI, US 02903		
	(Street and Number)			(City or Town, State, Country and Zip Code)		
Internet Web Site Address	WWW.BCBSRI.COM			401-459-1000		
Statutory Statement Contact	MICHAEL J. MARRONE			401-459-2183		
	(Name)			(Area Code) (Telephone Number) (Extension)		
	MICHAEL.MARRONE@BCBSRI.ORG			401-459-2183		
	(E-Mail Address)			(Fax Number)		

OFFICERS

	Name	Title
1.	MARTHA L. WOFFORD	PRESIDENT & CHIEF EXECUTIVE OFFICER
2.	MICHELE B. LEDERBERG	EVP. CHIEF ADMIN OFFICER & CHIEF LEGAL OFFICER
3.	MICHAEL J. MARRONE #	EXEC. VICE PRESIDENT & CHIEF FINANCIAL OFFICER

VICE-PRESIDENTS

Name	Title	Name	Title
ELAINE ALDERDICE #	VP - CORPORATE FINANCE & SOURCING O	CAROLYN BELISLE #	VP & CHIEF CORP SOCIAL RESPONSIBILITY
ANASTASIA BERGMAN	VP - CHIEF PEOPLE OFFICER	CHRISTOPHER G. BUSH	SVP - NETWORK PHARMACY & D&A
DAVID COMELLA	VP - CHIEF INFORMATION OFFICER	MELISSA B. CUMMINGS	EVP - CHIEF CUSTOMER OFFICER
CATHERINE DANGREMOND #	VP - POP HEALTH STRATEGY	TARA L. DEMOURA	SVP & CHIEF OPERATING OFFICER
JOHN DONOHUE	VP - GROUP SALES	JEREMY S. DUNCAN	VP - MARKETING
PETER N. LEFEBER	SVP - VALUE BASED CARE	BRIAN MACKINTOSH	VP - ACTUARIAL AND UNDERWRITING
KRISTEN MCLEAN	SVP - GENERAL COUNSEL	MICHAEL MENARD	VP - MEDICARE
CHRISTINE MUSIAL	VP - SHARED SERVICES	CHRISTINA PITNEY	SVP - GOVERNMENT PROGRAMS
FARAH SHAFI	EVP - CHIEF MEDICAL OFFICER	STACIA SOUCY #	VP - STRATEGIC FINANCIAL MANAGEMENT,
LINDA WINFREY	VP - CHIEF AUDITOR		

DIRECTORS OR TRUSTEES

ADENRELE ABIADÉ #	ERNEST ALMONTE	CHRISTOPHER BUFFERY	STEPHEN COHAN
CARA CROMWELL #	CHRISTOPHER CROSBY	NICHOLAS DENICE	JOSEPH DIAZ M.D.
LOUIS GIANCOLA	KAREN HAMMOND	MARGARET HOLLAND MCDUFF	MICHAEL ISRAELITE
GEORGE KUROSE #	SHARON MORRIS	WILLIAM MURRAY	KEVIN MURPHY #
ROBERT SANDERS	MARTHA TEMPLE	VICKI VIRGILIO	

State of RHODE ISLAND

County of PROVIDENCE ss

The officers of this reporting entity being duly sworn, each depose and say that they are the described officers of said reporting entity, and that on the reporting period stated above, all of the herein described assets were the absolute property of the said reporting entity, free and clear from any liens or claims thereon, except as herein stated, and that this statement, together with related exhibits, schedules and explanations therein contained, annexed or referred to, is a full and true statement of all the assets and liabilities and of the condition and affairs of the said reporting entity as of the reporting period stated above, and of its income and deductions therefrom for the period ended, and have been completed in accordance with the NAIC Annual Statement Instructions and Accounting Practices and Procedures manual except to the extent that: (1) state law may differ; or, (2) that state rules or regulations require differences in reporting not related to accounting practices and procedures, according to the best of their information, knowledge and belief, respectively. Furthermore, the scope of this attestation by the described officers also includes the related corresponding electronic filing with the NAIC, when required, that is an exact copy (except for formatting differences due to electronic filing) of the enclosed statement. The electronic filing may be requested by various regulators in lieu of or in addition to the enclosed statement.

(Signature)	(Signature)	(Signature)
MARTHA L. WOFFORD	MICHELE B. LEDERBERG	MICHAEL J. MARRONE
(Printed Name)	(Printed Name)	(Printed Name)
1.	2.	3.
PRESIDENT & CHIEF EXECUTIVE OFFICER	EVP. CHIEF ADMIN OFFICER & CHIEF LEGAL OFFICER	EXEC. VICE PRESIDENT & CHIEF FINANCIAL OFFICER
(Title)	(Title)	(Title)

Subscribed and sworn to (or affirmed) before me this on this
day of , 2025, by

a. Is this an original filing? [X] Yes [] No

b. If no:

1. State the amendment number

2. Date filed

3. Number of pages attached

ASSETS

	Current Year			Prior Year
	1	2	3	4
	Assets	Nonadmitted Assets	Net Admitted Assets (Cols. 1 - 2)	Net Admitted Assets
1. Bonds (Schedule D)	459,971,743		459,971,743	462,559,415
2. Stocks (Schedule D):				
2.1 Preferred stocks	19,046,132		19,046,132	21,128,948
2.2 Common stocks	115,092,151		115,092,151	105,454,145
3. Mortgage loans on real estate (Schedule B):				
3.1 First liens				
3.2 Other than first liens				
4. Real estate (Schedule A):				
4.1 Properties occupied by the company (less \$ 33,246,678 encumbrances)	48,450,577		48,450,577	45,321,428
4.2 Properties held for the production of income (less \$ 0 encumbrances)				
4.3 Properties held for sale (less \$ 0 encumbrances)				
5. Cash (\$ (6,617,842), Schedule E - Part 1), cash equivalents (\$ 6,253,781, Schedule E - Part 2), and short-term investments (\$ 0, Schedule DA)	(364,062)		(364,062)	24,864,668
6. Contract loans (including \$ 0 premium notes)				
7. Derivatives (Schedule DB)				
8. Other invested assets (Schedule BA)	32,297,927		32,297,927	39,562,025
9. Receivables for securities	826,709		826,709	191
10. Securities lending reinvested collateral assets (Schedule DL)				
11. Aggregate write-ins for invested assets				
12. Subtotals, cash and invested assets (Lines 1 to 11)	675,321,177		675,321,177	698,890,820
13. Title plants less \$ 0 charged off (for Title insurers only)				
14. Investment income due and accrued	3,280,935		3,280,935	3,190,224
15. Premiums and considerations:				
15.1 Uncollected premiums and agents' balances in the course of collection	24,639,510	8,617,919	16,021,591	27,400,929
15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$ 0 earned but unbilled premiums)				
15.3 Accrued retrospective premiums (\$ 472,436) and contracts subject to redetermination (\$ 34,870,000)	35,342,436		35,342,436	36,632,012
16. Reinsurance:				
16.1 Amounts recoverable from reinsurers	7,819,372		7,819,372	18,373,777
16.2 Funds held by or deposited with reinsured companies				
16.3 Other amounts receivable under reinsurance contracts				
17. Amounts receivable relating to uninsured plans	109,771,819	1,765,090	108,006,729	112,611,425
18.1 Current federal and foreign income tax recoverable and interest thereon				
18.2 Net deferred tax asset				
19. Guaranty funds receivable or on deposit				
20. Electronic data processing equipment and software	37,686,444	37,679,384	7,060	49,420
21. Furniture and equipment, including health care delivery assets (\$ 0)	418,285	418,285		
22. Net adjustment in assets and liabilities due to foreign exchange rates				
23. Receivables from parent, subsidiaries and affiliates				
24. Health care (\$ 116,309,289) and other amounts receivable	116,890,702	581,413	116,309,289	81,745,555
25. Aggregate write-ins for other-than-invested assets	82,124,711	26,611,887	55,512,824	46,900,191
26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	1,093,295,391	75,673,978	1,017,621,413	1,025,794,353
27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts				
28. Total (Lines 26 and 27)	1,093,295,391	75,673,978	1,017,621,413	1,025,794,353

DETAILS OF WRITE-IN LINES				
1101.				
1102.				
1103.				
1198. Summary of remaining write-ins for Line 11 from overflow page				
1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above)				
2501. OTHER RECEIVABLES	34,658,905	496,615	34,162,290	34,078,414
2502. PREPAID EXPENSES	23,629,128	23,629,128		
2503. FEP UNPAID CLAIMS	15,204,000		15,204,000	10,969,000
2598. Summary of remaining write-ins for Line 25 from overflow page	8,632,678	2,486,144	6,146,534	1,852,777
2599. Totals (Lines 2501 through 2503 plus 2598) (Line 25 above)	82,124,711	26,611,887	55,512,824	46,900,191

NONE

LIABILITIES, CAPITAL AND SURPLUS

	Current Year			Prior Year
	1 Covered	2 Uncovered	3 Total	4 Total
1. Claims unpaid (less \$ 0 reinsurance ceded)	223,707,846		223,707,846	172,331,717
2. Accrued medical incentive pool and bonus amounts	21,081,720		21,081,720	53,315,471
3. Unpaid claims adjustment expenses	24,802,847		24,802,847	20,437,460
4. Aggregate health policy reserves, including the liability of \$ 0 for medical loss ratio rebate per the Public Health Services Act	93,915,468		93,915,468	91,542,426
5. Aggregate life policy reserves				
6. Property/casualty unearned premium reserves				
7. Aggregate health claim reserves	5,326,000		5,326,000	4,496,000
8. Premiums received in advance	16,972,930		16,972,930	17,915,388
9. General expenses due or accrued	63,944,501		63,944,501	49,481,505
10.1. Current federal and foreign income tax payable and interest thereon (including \$ 0 on realized gains (losses))	1,205,538		1,205,538	918,410
10.2. Net deferred tax liability				
11. Ceded reinsurance premiums payable	2,085,953		2,085,953	654,765
12. Amounts withheld or retained for the account of others	6,761,151		6,761,151	1,189,803
13. Remittances and items not allocated	2,849,947		2,849,947	4,910,614
14. Borrowed money (including \$ 104,000,000 current) and interest thereon \$ 220,360 (including \$ 220,360 current)	104,220,360		104,220,360	70,098,133
15. Amounts due to parent, subsidiaries and affiliates				
16. Derivatives				
17. Payable for securities				
18. Payable for securities lending				
19. Funds held under reinsurance treaties (with \$ 0 authorized reinsurers, \$ 0 unauthorized reinsurers and \$ 0 certified reinsurers)				
20. Reinsurance in unauthorized and certified \$ (0) companies				
21. Net adjustments in assets and liabilities due to foreign exchange rates				
22. Liability for amounts held under uninsured plans	75,778,703		75,778,703	78,641,032
23. Aggregate write-ins for other liabilities (including \$ 22,896,689 current)	37,796,936		37,796,936	20,313,132
24. Total liabilities (Lines 1 to 23)	680,449,900		680,449,900	586,245,856
25. Aggregate write-ins for special surplus funds	X X X	X X X		
26. Common capital stock	X X X	X X X		
27. Preferred capital stock	X X X	X X X		
28. Gross paid in and contributed surplus	X X X	X X X		
29. Surplus notes	X X X	X X X		
30. Aggregate write-ins for other than special surplus funds	X X X	X X X		
31. Unassigned funds (surplus)	X X X	X X X	337,171,513	439,548,497
32. Less treasury stock, at cost:				
32.1 0 shares common (value included in Line 26 \$ 0)	X X X	X X X		
32.2 0 shares preferred (value included in Line 27 \$ 0)	X X X	X X X		
33. Total capital and surplus (Lines 25 to 31 minus Line 32)	X X X	X X X	337,171,513	439,548,497
34. Total liabilities, capital and surplus (Lines 24 and 33)	X X X	X X X	1,017,621,413	1,025,794,353

DETAILS OF WRITE-IN LINES				
2301. OTHER ACCOUNTS PAYABLE	36,451,460		36,451,460	19,451,827
2302. ACCRUED CAPITAL EXPENSES	2,660,181		2,660,181	1,436,141
2303. FEP & MISCELLANEOUS CLAIMS PAYABLES	136,468		136,468	232,012
2398. Summary of remaining write-ins for Line 23 from overflow page	(1,451,173)		(1,451,173)	(806,848)
2399. Totals (Lines 2301 through 2303 plus 2398) (Line 23 above)	37,796,936		37,796,936	20,313,132
2501.	X X X	X X X		
2502.	X X X	X X X		
2503.	X X X	X X X		
2598. Summary of remaining write-ins for Line 25 from overflow page	X X X	X X X		
2599. Totals (Lines 2501 through 2503 plus 2598) (Line 25 above)	X X X	X X X		
3001.	X X X	X X X		
3002.	X X X	X X X		
3003.	X X X	X X X		
3098. Summary of remaining write-ins for Line 30 from overflow page	X X X	X X X		
3099. Totals (Lines 3001 through 3003 plus 3098) (Line 30 above)	X X X	X X X		

NONE

NONE

STATEMENT OF REVENUE AND EXPENSES

	Current Year		Prior Year
	1 Uncovered	2 Total	3 Total
1. Member Months	X X X	4,659,193	4,251,422
2. Net premium income (including \$ 0 non-health premium income)	X X X	2,224,330,972	2,049,694,139
3. Change in unearned premium reserves and reserve for rate credits	X X X	(11,386,013)	(4,562,057)
4. Fee-for-service (net of \$ 0 medical expenses)	X X X		
5. Risk revenue	X X X		
6. Aggregate write-ins for other health care related revenues	X X X		
7. Aggregate write-ins for other non-health revenues	X X X		
8. Total revenues (Lines 2 to 7)	X X X	2,212,944,959	2,045,132,082
Hospital and Medical:			
9. Hospital/medical benefits		1,463,798,783	1,289,823,555
10. Other professional services		19,637,530	20,628,281
11. Outside referrals			
12. Emergency room and out-of-area		210,199,432	201,393,758
13. Prescription drugs		277,021,679	238,972,726
14. Aggregate write-ins for other hospital and medical		89,747,194	80,210,775
15. Incentive pool, withhold adjustments and bonus amounts		(23,774,987)	8,192,675
16. Subtotal (Lines 9 to 15)		2,036,629,631	1,839,221,770
Less:			
17. Net reinsurance recoveries		25,838,376	13,294,780
18. Total hospital and medical (Lines 16 minus 17)		2,010,791,255	1,825,926,990
19. Non-health claims (net)			
20. Claims adjustment expenses, including \$ 39,457,155 cost containment expenses		77,872,682	63,506,822
21. General administrative expenses		224,069,300	172,654,392
22. Increase in reserves for life and accident and health contracts (including \$ 0 increase in reserves for life only)		13,460,000	9,000,000
23. Total underwriting deductions (Lines 18 through 22)		2,326,193,237	2,071,088,204
24. Net underwriting gain or (loss) (Lines 8 minus 23)	X X X	(113,248,278)	(25,956,122)
25. Net investment income earned (Exhibit of Net Investment Income, Line 17)		17,504,529	14,859,094
26. Net realized capital gains (losses) less capital gains tax of \$ 0		(616,547)	(5,342,130)
27. Net investment gains (losses) (Lines 25 plus 26)		16,887,982	9,516,964
28. Net gain or (loss) from agents' or premium balances charged off [(amount recovered \$ 0) (amount charged off \$ 0)]			
29. Aggregate write-ins for other income or expenses		(18,658,096)	17,040,901
30. Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	X X X	(115,018,392)	601,743
31. Federal and foreign income taxes incurred	X X X		
32. Net income (loss) (Lines 30 minus 31)	X X X	(115,018,392)	601,743

DETAILS OF WRITE-IN LINES			
0601.	NONE	X X X	
0602.		X X X	
0603.		X X X	
0698. Summary of remaining write-ins for Line 06 from overflow page		X X X	
0699. Totals (Lines 0601 through 0603 plus 0698) (Line 06 above)		X X X	
0701.	NONE	X X X	
0702.		X X X	
0703.		X X X	
0798. Summary of remaining write-ins for Line 07 from overflow page		X X X	
0799. Totals (Lines 0701 through 0703 plus 0798) (Line 07 above)		X X X	
1401. MENTAL HEALTH		89,747,194	80,210,775
1402.			
1403.			
1498. Summary of remaining write-ins for Line 14 from overflow page			
1499. Totals (Lines 1401 through 1403 plus 1498) (Line 14 above)		89,747,194	80,210,775
2901. OTHER INCOME (NET OF PENALTIES)		748,379	931,832
2902. INCOME HISTORIC TAX CREDITS		180,000	180,000
2903. INDIGO COMMISSIONS		15,273	12,907
2998. Summary of remaining write-ins for Line 29 from overflow page		(19,601,748)	15,916,162
2999. Totals (Lines 2901 through 2903 plus 2998) (Line 29 above)		(18,658,096)	17,040,901

STATEMENT OF REVENUE AND EXPENSES (Continued)

	1	2
	Current Year	Prior Year
CAPITAL & SURPLUS ACCOUNT		
33. Capital and surplus prior reporting year	439,548,497	408,954,583
34. Net income or (loss) from Line 32	(115,018,392)	601,743
35. Change in valuation basis of aggregate policy and claim reserves		
36. Change in net unrealized capital gains (losses) less capital gains tax of \$ 0	(1,450,177)	32,977,777
37. Change in net unrealized foreign exchange capital gain or (loss)		
38. Change in net deferred income tax		
39. Change in nonadmitted assets	13,447,261	(2,535,923)
40. Change in unauthorized and certified reinsurance		
41. Change in treasury stock		
42. Change in surplus notes		
43. Cumulative effect of changes in accounting principles		
44. Capital Changes:		
44.1 Paid in		
44.2 Transferred from surplus (Stock Dividend)		
44.3 Transferred to surplus		
45. Surplus adjustments:		
45.1 Paid in		
45.2 Transferred to capital (Stock Dividend)		
45.3 Transferred from capital		
46. Dividends to stockholders		
47. Aggregate write-ins for gains or (losses) in surplus	644,324	(449,683)
48. Net change in capital and surplus (Lines 34 to 47)	(102,376,984)	30,593,914
49. Capital and surplus end of reporting year (Line 33 plus 48)	337,171,513	439,548,497

DETAILS OF WRITE-IN LINES		
4701. OTHER POSTEMPLOYMENT BENEFITS	403,041	(383,582)
4702. NON-QUALIFIED PENSION PLAN	241,283	(66,101)
4703.		
4798. Summary of remaining write-ins for Line 47 from overflow page		
4799. Totals (Lines 4701 through 4703 plus 4798) (Line 47 above)	644,324	(449,683)

CASH FLOW

	1	2
Cash from Operations	Current Year	Prior Year
1. Premiums collected net of reinsurance	2,224,968,793	2,043,301,361
2. Net investment income	17,344,333	15,196,514
3. Miscellaneous income	(3,605,632)	18,400,263
4. Total (Lines 1 through 3)	2,238,707,494	2,076,898,138
5. Benefit and loss related payments	2,023,395,226	1,815,371,504
6. Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7. Commissions, expenses paid and aggregate write-ins for deductions	252,693,173	219,666,922
8. Dividends paid to policyholders		
9. Federal and foreign income taxes paid (recovered) net of \$ 0 tax on capital gains (losses)	(286,084)	
10. Total (Lines 5 through 9)	2,275,802,315	2,035,038,426
11. Net cash from operations (Line 4 minus Line 10)	(37,094,821)	41,859,712
Cash from Investments		
12. Proceeds from investments sold, matured or repaid:		
12.1 Bonds	208,065,649	69,812,338
12.2 Stocks	58,299,944	29,283,488
12.3 Mortgage loans		
12.4 Real estate		
12.5 Other invested assets		
12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		
12.7 Miscellaneous proceeds		63
12.8 Total investment proceeds (Lines 12.1 to 12.7)	266,365,593	99,095,889
13. Cost of investments acquired (long-term only):		
13.1 Bonds	214,373,854	77,423,429
13.2 Stocks	51,170,725	31,360,178
13.3 Mortgage loans		
13.4 Real estate	5,485,801	5,182,554
13.5 Other invested assets	521,674	444,490
13.6 Miscellaneous applications	826,517	2,327,117
13.7 Total investments acquired (Lines 13.1 to 13.6)	272,378,571	116,737,768
14. Net increase (decrease) in contract loans and premium notes		
15. Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(6,012,978)	(17,641,879)
Cash from Financing and Miscellaneous Sources		
16. Cash provided (applied):		
16.1 Surplus notes, capital notes		
16.2 Capital and paid in surplus, less treasury stock		
16.3 Borrowed funds	34,122,227	22,057,583
16.4 Net deposits on deposit-type contracts and other insurance liabilities		
16.5 Dividends to stockholders		
16.6 Other cash provided (applied)	(16,243,158)	(17,091,618)
17. Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	17,879,069	4,965,965
RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18. Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	(25,228,730)	29,183,798
19. Cash, cash equivalents and short-term investments:		
19.1 Beginning of year	24,864,668	(4,319,130)
19.2 End of year (Line 18 plus Line 19.1)	(364,062)	24,864,668

Note: Supplemental disclosures of cash flow information for non-cash transactions:

20.0001		
20.0002		
20.0003		

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

	1	Comprehensive (Hospital & Medical)		4	5	6	7	8	9	10	11	12	13	14
		2	3											
	Total	Individual	Group	Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefit Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
1. Net premium income	2,224,330.97	149,128,227	751,767,111	59,564,143	854,721	28,771,682	175,832,956	1,027,444,18					30,967,952	
2. Change in unearned premium reserves and reserve for rate credit	(11,386,013)						(11,386,013)							
3. Fee-for-service (net of \$ 0 medical expenses)														X X X
4. Risk revenue														X X X
5. Aggregate write-ins for other health care related revenues														X X X
6. Aggregate write-ins for other non-health care related revenues		X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	
7. Total revenues (Lines 1 to 6)	2,212,944.95	149,128,227	751,767,111	59,564,143	854,721	28,771,682	164,446,943	1,027,444,18					30,967,952	
8. Hospital/medical benefits	1,463,798.78	67,222,755	356,335,896	47,664,620			110,083,789	857,690,263					24,801,460	X X X
9. Other professional services	19,637,530				585,252	19,052,278								X X X
10. Outside referrals														X X X
11. Emergency room and out-of-area	210,199,432	28,951,802	147,261,197					33,986,433						X X X
12. Prescription drugs	277,021,679	33,536,032	128,879,155	944,883			31,145,090	68,666,629					13,849,890	X X X
13. Aggregate write-ins for other hospital and medical	89,747,194	12,003,644	44,374,046				10,939,096	22,430,408						X X X
14. Incentive pool, withhold adjustments and bonus amounts	(23,774,987)	(60,039)	(11,717,605)					(11,997,343)						X X X
15. Subtotal (Lines 8 to 14)	2,036,629.63	141,654,194	665,132,689	48,609,503	585,252	19,052,278	152,167,975	970,776,390					38,651,350	X X X
16. Net reinsurance recoveries	25,838,376	9,675,199	2,839,486										13,323,691	X X X
17. Total hospital and medical (Lines 15 minus 16)	2,010,791.25	131,978,995	662,293,203	48,609,503	585,252	19,052,278	152,167,975	970,776,390					25,327,659	X X X
18. Non-health claims (net)		X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	
19. Claims adjustment expenses including \$ 39,457,155 cost containment expenses	77,872,682	5,474,513	28,728,217	2,722,414	91,662	1,275,591	4,210,482	34,644,372					725,431	
20. General administrative expenses	224,069,300	14,990,956	92,957,224	7,454,835	250,999	3,492,972	8,068,555	94,867,299					1,986,460	
21. Increase in reserves for accident and health contracts	13,460,000	(4,210,000)	540,000	(150,000)				17,280,000						X X X
22. Increase in reserves for life contracts		X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	
23. Total underwriting deductions (Lines 17 to 22)	2,326,193.23	148,234,464	784,518,644	58,636,752	927,913	23,820,841	164,447,012	1,117,568,06					28,039,550	
24. Net underwriting gain or (loss) (Line 7 minus Line 23)	(113,248,278)	893,763	(32,751,533)	927,391	(73,192)	4,950,841	(69)	(90,123,881)					2,928,402	

DETAILS OF WRITE-IN LINES														
050														X X X
050														X X X
050														X X X
059	Summary of remaining write-ins for Line 05 from overflow page													X X X
059	Totals (Lines 0501 through 0503 plus 0598) (Line 05 above)													X X X
060		X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	
060		X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	
060		X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	
069	Summary of remaining write-ins for Line 06 from overflow page	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	
069	Totals (Lines 0601 through 0603 plus 0698) (Line 06 above)	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	X X X	
130	MENTAL HEALTH	89,747,194	12,003,644	44,374,046				10,939,096	22,430,408					X X X
130														X X X
130														X X X
139	Summary of remaining write-ins for Line 13 from overflow page													X X X
139	Totals (Lines 1301 through 1303 plus 1398) (Line 13 above)	89,747,194	12,003,644	44,374,046				10,939,096	22,430,408					X X X

UNDERWRITING AND INVESTMENT EXHIBIT
PART 1 – PREMIUMS

Line of Business	1 Direct Business	2 Reinsurance Assumed	3 Reinsurance Ceded	4 Net Premium Income (Cols. 1 + 2 - 3)
1. Comprehensive (hospital and medical) individual	149,478,066		349,839	149,128,227
2. Comprehensive (hospital and medical) group	753,865,816		1,976,067	751,889,749
3. Medicare Supplement	59,564,143			59,564,143
4. Vision only	854,721			854,721
5. Dental only	28,771,682			28,771,682
6. Federal Employees Health Benefits Plan	164,446,943			164,446,943
7. Title XVIII – Medicare	1,027,444,180			1,027,444,180
8. Title XIX – Medicaid				
9. Credit A&H				
10. Disability Income				
11. Long-Term Care				
12. Other health	38,385,819		7,540,503	30,845,316
13. Health subtotal (Lines 1 through 12)	2,222,811,370		9,866,409	2,212,944,961
14. Life				
15. Property/casualty				
16. Totals (Lines 13 to 15)	2,222,811,370		9,866,409	2,212,944,961

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 – CLAIMS INCURRED DURING THE YEAR

	1	Comprehensive (Hospital & Medical)		4	5	6	7 Federal Employees Health Benefits Plan	8 Title XVIII Medicare	9 Title XIX Medicaid	10 Credit A&H	11 Disability Income	12 Long-Term Care	13 Other Health	14 Other Non-Health
		2	3											
		Individual	Group											
	Total			Medicare Supplement	Vision Only	Dental Only								
1. Payments during the year:														
1.1 Direct	2,039,656,651	138,735,923	685,541,600	50,203,159	269,180	18,942,536	146,904,149	960,472,754					38,587,350	
1.2 Reinsurance assumed														
1.3 Reinsurance ceded	36,392,781	19,204,284	3,742,674										13,445,823	
1.4 Net	2,003,263,870	119,531,639	681,798,926	50,203,159	269,180	18,942,536	146,904,149	960,472,754					25,141,527	
2. Paid medical incentive pools and bonuses	8,458,764	1,705,269	13,582,160					(6,828,665)						
3. Claim liability December 31, current year from Part 2A:														
3.1 Direct	223,707,845	15,217,728	64,712,749	5,940,123	316,072	1,325,235	16,485,002	114,485,936					5,225,000	
3.2 Reinsurance assumed														
3.3 Reinsurance ceded														
3.4 Net	223,707,845	15,217,728	64,712,749	5,940,123	316,072	1,325,235	16,485,002	114,485,936					5,225,000	
4. Claim reserve December 31, current year from Part 2D:														
4.1 Direct	5,326,000	5,326,000												
4.2 Reinsurance assumed														
4.3 Reinsurance ceded														
4.4 Net	5,326,000	5,326,000												
5. Accrued medical incentive pools and bonuses, current year	21,081,720	930,369	13,349,559					6,801,792						
6. Net healthcare receivables (a)	31,458,161	1,626,818	18,602,394			10,493	35,487	11,182,969						
7. Amounts recoverable from reinsurers December 31, current	7,819,372	7,272,705	38,503										508,164	
8. Claim liability December 31, prior year from Part 2A:														
8.1 Direct	172,331,717	11,442,600	54,801,661	7,533,779		1,205,000	11,185,689	81,001,988					5,161,000	
8.2 Reinsurance assumed														
8.3 Reinsurance ceded														
8.4 Net	172,331,717	11,442,600	54,801,661	7,533,779		1,205,000	11,185,689	81,001,988					5,161,000	
9. Claim reserve December 31, prior year from Part 2D:														
9.1 Direct	4,496,000	4,496,000												
9.2 Reinsurance assumed														
9.3 Reinsurance ceded														
9.4 Net	4,496,000	4,496,000												
10. Accrued medical incentive pools and bonuses, prior year	53,315,471	2,695,677	38,649,324					11,970,470						
11. Amounts recoverable from reinsurers December 31, prior ye	18,373,777	16,801,790	941,691										630,296	
12. Incurred benefits:														
12.1 Direct	2,060,404,618	141,714,233	676,850,294	48,609,503	585,252	19,052,278	152,167,975	982,773,733					38,651,350	
12.2 Reinsurance assumed														
12.3 Reinsurance ceded	25,838,376	9,675,199	2,839,486										13,323,691	
12.4 Net	2,034,566,242	132,039,034	674,010,808	48,609,503	585,252	19,052,278	152,167,975	982,773,733					25,327,659	
13. Incurred medical incentive pools and bonuses	(23,774,987)	(60,039)	(11,717,605)					(11,997,343)						

(a) Excludes \$ 0 loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A – CLAIMS LIABILITY END OF CURRENT YEAR

	1	Comprehensive (Hospital & Medical)		4	5	6	7	8	9	10	11	12	13	14
		2	3											
		Individual	Group											
	Total			Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
1. Reported in Process of Adjustment:														
1.1 Direct	126,536,064	7,749,219	26,432,093	144,371	316,072	430,277	4,728,258	81,510,774					5,225,000	
1.2 Reinsurance assumed														
1.3 Reinsurance ceded														
1.4 Net	126,536,064	7,749,219	26,432,093	144,371	316,072	430,277	4,728,258	81,510,774					5,225,000	
2. Incurred but Unreported:														
2.1 Direct	97,171,781	7,468,509	38,280,656	5,795,752		894,958	11,756,744	32,975,162						
2.2 Reinsurance assumed														
2.3 Reinsurance ceded														
2.4 Net	97,171,781	7,468,509	38,280,656	5,795,752		894,958	11,756,744	32,975,162						
3. Amounts Withheld from Paid Claims and Capitations:														
3.1 Direct														
3.2 Reinsurance assumed														
3.3 Reinsurance ceded														
3.4 Net														
4. TOTALS:														
4.1 Direct	223,707,845	15,217,728	64,712,749	5,940,123	316,072	1,325,235	16,485,002	114,485,936					5,225,000	
4.2 Reinsurance assumed														
4.3 Reinsurance ceded														
4.4 Net	223,707,845	15,217,728	64,712,749	5,940,123	316,072	1,325,235	16,485,002	114,485,936					5,225,000	

UNDERWRITING AND INVESTMENT EXHIBIT
PART 2B – ANALYSIS OF CLAIMS UNPAID – PRIOR YEAR-NET OF REINSURANCE

Line of Business	Claims Paid During the Year		Claim Reserve and Claim Liability December 31 of Current Year		5	6
	1 On Claims Incurred Prior to January 1 of Current Year	2 On Claims Incurred During the Year	3 On Claims Unpaid December 31 of Prior Year	4 On Claims Incurred During the Year	Claims Incurred in Prior Years (Columns 1 + 3)	Estimated Claim Reserve and Claim Liability December 31 of Prior Year
1. Comprehensive (hospital and medical) individual	8,156,841	128,233,623	4,303	20,539,425	8,161,144	15,938,600
2. Comprehensive (hospital and medical) group	45,051,130	674,018,343	1,147,775	63,564,974	46,198,905	54,801,661
3. Medicare Supplement	4,995,909	45,207,250	7,592	5,932,531	5,003,501	7,533,779
4. Vision only	19,749	249,431		316,072	19,749	
5. Dental only	970,036	17,972,500	4,449	1,320,786	974,485	1,205,000
6. Federal Employees Health Benefits Plan	11,029,112	135,875,036	177,847	16,307,155	11,206,959	11,185,689
7. Title XVIII – Medicare	49,314,383	952,248,724	21,929,369	92,556,567	71,243,752	81,001,988
8. Title XIX – Medicaid						
9. Credit A&H						
10. Disability Income						
11. Long-Term Care						
12. Other health	1,959,149	23,304,510	1,306,250	3,918,750	3,265,399	5,161,000
13. Health subtotal (Lines 1 to 12)	121,496,309	1,977,109,417	24,577,585	204,456,260	146,073,894	176,827,717
14. Health care receivables (a)	35,901,368	75,589,842		4,796,854	35,901,368	42,452
15. Other non-health						
16. Medical incentive pools and bonus amounts	6,654,227	1,804,537	6,660,257	14,421,463	13,314,484	53,315,471
17. Totals (Lines 13 - 14 + 15 + 16)	92,249,168	1,903,324,112	31,237,842	214,080,869	123,487,010	230,100,736

11

(a) Excludes \$ (602,638) loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT
PART 2C – DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)
Hospital & Medical

Section A – Paid Health Claims

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior		662,738	705,400	705,400	705,290	705,290
2. 2020		606,294	648,689	648,689	648,891	648,891
3. 2021	X X X		659,193	704,448	704,526	704,526
4. 2022	X X X		X X X	637,782	682,402	682,402
5. 2023	X X X		X X X	X X X	758,283	758,283
6. 2024	X X X		X X X	X X X	X X X	766,537

Section B – Incurred Health Claims

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior		749,695	708,877	705,400	705,318	704,991
2. 2020		691,736	654,981	648,689	648,891	648,837
3. 2021	X X X		722,943	706,225	704,526	704,513
4. 2022	X X X		X X X	732,412	713,349	683,017
5. 2023	X X X		X X X	X X X	837,227	813,177
6. 2024	X X X		X X X	X X X	X X X	856,748

Section C – Incurred Year Health Claims and Claims Adjustment Expense Ratio

Years in which Premiums were Earned and Claims were Incurred		1	2	3	4	5	6	7	8	9	10
		Premiums Earned	Claims Payments	Claim Adjustment Expense Payments	(Col. 3 / 2) Percent	Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	(Col. 5 / 1) Percent	Claims Unpaid	Unpaid Claims Adjustment Expenses	Total Claims and Claims Adjustment Expense Incurred (Col. 5 + 7 + 8)	(Col. 9 / 1) Percent
1. 2020		807,111	606,294			606,294	75.119			606,294	75.119
2. 2021		837,050	659,193			659,193	78.752			659,193	78.752
3. 2022		834,265	637,782			637,782	76.448			637,782	76.448
4. 2023		881,643	758,283	14,911	1.966	773,194	87.699	7,187	742	781,123	88.599
5. 2024		900,895	766,537	14,911	1.945	781,448	86.741	90,211	9,320	880,979	97.789

UNDERWRITING AND INVESTMENT EXHIBIT
PART 2C – DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)
Medicare Supplement

Section A – Paid Health Claims

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior		51,452	51,091	51,149	51,123	51,108
2. 2020		41,172	44,594	44,582	44,551	44,498
3. 2021		X X X	43,711	48,770	48,914	48,936
4. 2022		X X X	X X X	42,441	48,179	48,177
5. 2023		X X X	X X X	X X X	44,955	49,963
6. 2024		X X X	X X X	X X X	X X X	45,207

Section B – Incurred Health Claims

12MS

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior		708,877	705,400	705,318	51,123	51,108
2. 2020		691,736	654,981	648,689	44,551	44,498
3. 2021		X X X	722,943	706,225	48,914	48,936
4. 2022		X X X	X X X	732,412	48,304	48,177
5. 2023		X X X	X X X	X X X	52,365	49,971
6. 2024		X X X	X X X	X X X	X X X	51,140

Section C – Incurred Year Health Claims and Claims Adjustment Expense Ratio

Years in which Premiums were Earned and Claims were Incurred		1	2	3	4	5	6	7	8	9	10
		Premiums Earned	Claims Payments	Claim Adjustment Expense Payments	(Col. 3 / 2) Percent	Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	(Col. 5 / 1) Percent	Claims Unpaid	Unpaid Claims Adjustment Expenses	Total Claims and Claims Adjustment Expense Incurred (Col. 5 + 7 + 8)	(Col. 9 / 1) Percent
1. 2020		807,111	606,294			606,294	75.119			606,294	75.119
2. 2021		837,050	659,193			659,193	78.752			659,193	78.752
3. 2022		834,265	637,782			637,782	76.448			637,782	76.448
4. 2023		57,618	44,955	913	2.031	45,868	79.607	8	1	45,877	79.623
5. 2024		59,564	45,207	913	2.020	46,120	77.429	5,933	615	52,668	88.423

UNDERWRITING AND INVESTMENT EXHIBIT
PART 2C – DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)
Dental Only

Section A – Paid Health Claims

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior		22,073	22,083	22,084	22,085	22,084
2. 2020		16,914	17,794	17,807	17,811	17,813
3. 2021		X X X	20,031	20,915	20,926	20,927
4. 2022		X X X	X X X	19,247	19,247	19,255
5. 2023		X X X	X X X	X X X	19,015	19,975
6. 2024		X X X	X X X	X X X	X X X	17,973

Section B – Incurred Health Claims

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior		22,077	22,083	22,084	22,085	22,084
2. 2020		18,095	17,802	17,807	17,811	17,813
3. 2021		X X X	21,151	20,926	20,926	20,927
4. 2022		X X X	X X X	20,261	20,138	19,255
5. 2023		X X X	X X X	X X X	20,220	19,980
6. 2024		X X X	X X X	X X X	X X X	19,293

Section C – Incurred Year Health Claims and Claims Adjustment Expense Ratio

Years in which Premiums were Earned and Claims were Incurred		1	2	3	4	5	6	7	8	9	10
		Premiums Earned	Claims Payments	Claim Adjustment Expense Payments	(Col. 3 / 2) Percent	Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	(Col. 5 / 1) Percent	Claims Unpaid	Unpaid Claims Adjustment Expenses	Total Claims and Claims Adjustment Expense Incurred (Col. 5 + 7 + 8)	(Col. 9 / 1) Percent
1. 2020		28,158	16,914			16,914	60.068			16,914	60.068
2. 2021		28,818	20,031			20,031	69.509			20,031	69.509
3. 2022		29,030	19,247			19,247	66.300			19,247	66.300
4. 2023		28,988	19,015	345	1.814	19,360	66.786	4	1	19,365	66.804
5. 2024		28,772	17,973	345	1.920	18,318	63.666	1,321	232	19,871	69.064

UNDERWRITING AND INVESTMENT EXHIBIT
PART 2C – DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)
Vision Only

Section A – Paid Health Claims

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior		342	342	342	342	342
2. 2020		440	449	449	449	449
3. 2021	X X X		424	440	440	440
4. 2022	X X X		X X X	498	519	519
5. 2023	X X X		X X X	X X X	538	558
6. 2024	X X X		X X X	X X X	X X X	249

Section B – Incurred Health Claims

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior		342	342	342	342	342
2. 2020		440	449	449	449	449
3. 2021	X X X		424	440	440	440
4. 2022	X X X		X X X	498	519	519
5. 2023	X X X		X X X	X X X	538	558
6. 2024	X X X		X X X	X X X	X X X	249

Section C – Incurred Year Health Claims and Claims Adjustment Expense Ratio

Years in which Premiums were Earned and Claims were Incurred		1 Premiums Earned	2 Claims Payments	3 Claim Adjustment Expense Payments	4 (Col. 3 / 2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5 / 1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5 + 7 + 8)	10 (Col. 9 / 1) Percent
1. 2020		953	440			440	46.170			440	46.170
2. 2021		954	424			424	44.444			424	44.444
3. 2022		844	498			498	59.005			498	59.005
4. 2023		862	538			538	62.413			538	62.413
5. 2024		855	249			249	29.123	316		565	66.082

UNDERWRITING AND INVESTMENT EXHIBIT
PART 2C – DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)
Fed Emp Health Benefits Plan

Section A – Paid Health Claims

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior		102,865	93,054	93,018	93,025	92,992
2. 2020		95,133	105,493	105,543	105,537	105,522
3. 2021	X X X		105,693	115,646	115,870	115,852
4. 2022	X X X		X X X	108,830	119,171	119,451
5. 2023	X X X		X X X	X X X	125,840	136,496
6. 2024	X X X		X X X	X X X	X X X	135,875

Section B – Incurred Health Claims

12FE

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior		109,325	109,228	93,018	93,025	92,992
2. 2020		103,078	106,063	105,543	105,537	105,522
3. 2021	X X X		115,907	115,800	115,870	115,852
4. 2022	X X X		X X X	118,461	119,418	119,451
5. 2023	X X X		X X X	X X X	136,779	136,674
6. 2024	X X X		X X X	X X X	X X X	152,182

Section C – Incurred Year Health Claims and Claims Adjustment Expense Ratio

Years in which Premiums were Earned and Claims were Incurred	1	2	3	4	5	6	7	8	9	10
	Premiums Earned	Claims Payments	Claim Adjustment Expense Payments	(Col. 3 / 2) Percent	Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	(Col. 5 / 1) Percent	Claims Unpaid	Unpaid Claims Adjustment Expenses	Total Claims and Claims Adjustment Expense Incurred (Col. 5 + 7 + 8)	(Col. 9 / 1) Percent
1. 2020	116,045	95,133			95,133	81.979			95,133	81.979
2. 2021	129,716	105,693			105,693	81.480			105,693	81.480
3. 2022	129,006	108,830			108,830	84.360			108,830	84.360
4. 2023	150,107	125,840	2,672	2.123	128,512	85.614	178	19	128,709	85.745
5. 2024	164,447	135,875	2,672	1.967	138,547	84.250	16,307	1,784	156,638	95.251

UNDERWRITING AND INVESTMENT EXHIBIT
PART 2C – DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)
Title XVIII - Medicare

Section A – Paid Health Claims

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid				
	1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior	507,508	507,513	507,616	507,676	507,718
2. 2020	498,362	536,807	536,617	536,666	536,635
3. 2021	X X X	587,167	622,520	622,312	622,437
4. 2022	X X X	X X X	665,766	700,130	700,457
5. 2023	X X X	X X X	X X X	781,810	819,042
6. 2024	X X X	X X X	X X X	X X X	909,856

Section B – Incurred Health Claims

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
	1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior	510,982	507,513	507,616	507,676	507,718
2. 2020	568,671	546,449	536,617	536,666	536,635
3. 2021	X X X	675,496	623,667	622,312	622,437
4. 2022	X X X	X X X	730,100	705,614	700,457
5. 2023	X X X	X X X	X X X	871,493	841,597
6. 2024	X X X	X X X	X X X	X X X	1,010,728

Section C – Incurred Year Health Claims and Claims Adjustment Expense Ratio

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payments	3 Claim Adjustment Expense Payments	4 (Col. 3 / 2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5 / 1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5 + 7 + 8)	10 (Col. 9 / 1) Percent
1. 2020	669,128	498,362			498,362	74.479			498,362	74.479
2. 2021	714,122	587,167			587,167	82.222			587,167	82.222
3. 2022	808,184	665,766			665,766	82.378			665,766	82.378
4. 2023	900,597	781,810	17,448	2.232	799,258	88.748	22,555	2,152	823,965	91.491
5. 2024	1,027,444	909,856	17,448	1.918	927,304	90.253	100,872	9,623	1,037,799	101.008

UNDERWRITING AND INVESTMENT EXHIBIT
PART 2C – DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
 (\$000 Omitted)
 Title XIX - Medicaid

Section A – Paid Health Claims

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid				
	1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior					
2. 2020					
3. 2021					
4. 2022	X X X				
5. 2023	X X X	X X X			
6. 2024	X X X	X X X	X X X		

Section B – Incurred Health Claims

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
	1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior					
2. 2020					
3. 2021	X X X				
4. 2022	X X X	X X X			
5. 2023	X X X	X X X	X X X		
6. 2024	X X X	X X X	X X X	X X X	

Section C – Incurred Year Health Claims and Claims Adjustment Expense Ratio

[illegible]

UNDERWRITING AND INVESTMENT EXHIBIT
PART 2C – DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)
Other

Section A – Paid Health Claims

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior		16,317	16,317	16,317	16,317	16,317
2. 2020		13,948	97,935	97,935	97,935	97,935
3. 2021	X X X		17,621	206,663	206,663	206,663
4. 2022	X X X		X X X	15,878	20,162	20,162
5. 2023	X X X		X X X	X X X	14,859	15,130
6. 2024	X X X		X X X	X X X	X X X	23,305

Section B – Incurred Health Claims

12.01

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior		16,317	16,317	16,317	16,317	16,317
2. 2020		19,767	97,935	97,935	97,935	97,935
3. 2021	X X X		22,725	206,663	206,663	206,663
4. 2022	X X X		X X X	22,318	21,039	20,162
5. 2023	X X X		X X X	X X X	19,143	16,436
6. 2024	X X X		X X X	X X X	X X X	27,223

Section C – Incurred Year Health Claims and Claims Adjustment Expense Ratio

Years in which Premiums were Earned and Claims were Incurred	1	2	3	4	5	6	7	8	9	10
	Premiums Earned	Claims Payments	Claim Adjustment Expense Payments	(Col. 3 / 2) Percent	Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	(Col. 5 / 1) Percent	Claims Unpaid	Unpaid Claims Adjustment Expenses	Total Claims and Claims Adjustment Expense Incurred (Col. 5 + 7 + 8)	(Col. 9 / 1) Percent
1. 2020	25,168	13,948			13,948	55.420			13,948	55.420
2. 2021	24,510	17,621			17,621	71.893			17,621	71.893
3. 2022	23,878	15,878			15,878	66.496			15,878	66.496
4. 2023	25,317	14,859	460	3.096	15,319	60.509	1,306	78	16,703	65.975
5. 2024	30,968	23,305	460	1.974	23,765	76.741	3,919	233	27,917	90.148

UNDERWRITING AND INVESTMENT EXHIBIT
PART 2C – DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)
Grand Total

Section A – Paid Health Claims

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid				
	1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior	1,363,295	1,395,800	1,395,926	1,395,858	1,395,851
2. 2020	1,272,263	1,451,761	1,451,622	1,451,840	1,451,743
3. 2021	X X X	1,433,840	1,719,402	1,719,651	1,719,781
4. 2022	X X X	X X X	1,490,442	1,589,810	1,590,423
5. 2023	X X X	X X X	X X X	1,745,300	1,799,447
6. 2024	X X X	X X X	X X X	X X X	1,899,002

Section B – Incurred Health Claims

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
	1 2020	2 2021	3 2022	4 2023	5 2024
1. Prior	2,117,615	2,069,760	2,050,095	1,395,886	1,395,552
2. 2020	2,093,523	2,078,660	2,055,729	1,451,840	1,451,689
3. 2021	X X X	2,281,589	2,379,946	1,719,651	1,719,768
4. 2022	X X X	X X X	2,356,462	1,628,381	1,591,038
5. 2023	X X X	X X X	X X X	1,937,765	1,878,393
6. 2024	X X X	X X X	X X X	X X X	2,117,563

Section C – Incurred Year Health Claims and Claims Adjustment Expense Ratio

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payments	3 Claim Adjustment Expense Payments	4 (Col. 3 / 2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5 / 1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5 + 7 + 8)	10 (Col. 9 / 1) Percent
1. 2020	2,453,674	1,837,385			1,837,385	74.883			1,837,385	74.883
2. 2021	2,572,220	2,049,322			2,049,322	79.671			2,049,322	79.671
3. 2022	2,659,472	2,085,783			2,085,783	78.428			2,085,783	78.428
4. 2023	2,045,132	1,745,300	36,749	2.106	1,782,049	87.136	31,238	2,993	1,816,280	88.810
5. 2024	2,212,945	1,899,002	36,749	1.935	1,935,751	87.474	218,879	21,807	2,176,437	98.350

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D – AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	1	Comprehensive (Hospital & Medical)		4	5	6	7	8	9	10	11	12	13
		2	3										
		Individual	Group										
	Total			Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A & H	Disability Income	Long-Term Care	Other
1. Unearned premium reserves	585,857						585,857						
2. Additional policy reserves (a)	52,860,000	5,590,000	19,140,000	650,000				27,480,000					
3. Reserve for future contingent benefits													
4. Reserve for rate credits or experience rating refunds (including \$ 0 for investment income)													
5. Aggregate write-ins for other policy reserves	40,469,611							40,469,611					
6. Totals (gross)	93,915,468	5,590,000	19,140,000	650,000			585,857	67,949,611					
7. Reinsurance ceded													
8. Totals (Net) (Page 3, Line 4)	93,915,468	5,590,000	19,140,000	650,000			585,857	67,949,611					
9. Present value of amounts not yet due on claims													
10. Reserve for future contingent benefits	627,000	102,450	524,550										
11. Aggregate write-ins for other claim reserves	4,699,000	4,699,000											
12. Totals (gross)	5,326,000	4,801,450	524,550										
13. Reinsurance ceded													
14. Totals (Net) (Page 3, Line 7)	5,326,000	4,801,450	524,550										

DETAILS OF WRITE-IN LINES													
0501. RETROSPECTIVE RISK ADJUSTER	40,469,611							40,469,611					
0502.													
0503.													
0598. Summary of remaining write-ins for Line 05 from overflow page													
0599. Totals (Lines 0501 through 0503 plus 0598) (Line 05 above)	40,469,611							40,469,611					
1101. MATERNITY	4,699,000	4,699,000											
1102.													
1103.													
1198. Summary of remaining write-ins for Line 11 from overflow page													
1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above)	4,699,000	4,699,000											

(a) Includes \$ 0 premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 – ANALYSIS OF EXPENSES

	Claim Adjustment Expenses		3	4	5
	1	2			
	Cost Containment Expenses	Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1. Rent (\$ 6,313,968 for occupancy of own building)		43,483	5,545,910		5,589,393
2. Salaries, wages and other benefits	33,295,185	16,314,575	68,115,144		117,724,904
3. Commissions (less \$ 0 ceded plus \$ 0 assumed)			19,241,307		19,241,307
4. Legal fees and expenses		15,195	4,530,715		4,545,910
5. Certifications and accreditation fees					
6. Auditing, actuarial and other consulting services	2,029,122	1,012,874	22,948,203		25,990,199
7. Traveling expenses	84,764	85,240	984,793		1,154,797
8. Marketing and advertising	4,321	3,999	3,735,780		3,744,100
9. Postage, express and telephone	131,620	1,131,019	2,527,629		3,790,268
10. Printing and office supplies	4,775	1,139,416	2,174,033		3,318,224
11. Occupancy, depreciation and amortization	19,605	103,064	1,720,195		1,842,864
12. Equipment					
13. Cost or depreciation of EDP equipment and software	8,673,414	4,281,565	44,193,482		57,148,461
14. Outsourced services including EDP, claims, and other services	5,432,107	16,060,936	65,194,409		86,687,452
15. Boards, bureaus and association fees	3,619	20,456	1,828,601		1,852,676
16. Insurance, except on real estate		1,587	3,689,548		3,691,135
17. Collection and bank service charges					
18. Group service and administration fees			2,867,667		2,867,667
19. Reimbursements by uninsured plans	(11,024,541)	(10,654,602)	(59,362,247)		(81,041,390)
20. Reimbursements from fiscal intermediaries					
21. Real estate expenses				2,050,295	2,050,295
22. Real estate taxes				1,759,481	1,759,481
23. Taxes, licenses and fees:					
23.1 State and local insurance taxes			2,686,068		2,686,068
23.2 State premium taxes			20,431,826		20,431,826
23.3 Regulatory authority licenses and fees	13,215	8,092	5,482,963		5,504,270
23.4 Payroll taxes	2,047,553	963,388	3,761,046		6,771,987
23.5 Other (excluding federal income and real estate taxes)					
24. Investment expenses not included elsewhere					
25. Aggregate write-ins for expenses	(1,257,604)	7,885,240	1,772,228	1,428,044	9,827,908
26. Total expenses incurred (Lines 1 to 25)	39,457,155	38,415,527	224,069,300	5,237,820	(a) 307,179,802
27. Less expenses unpaid December 31, current year	12,613,045	12,189,801	63,944,502		88,747,348
28. Add expenses unpaid December 31, prior year	9,671,551	10,765,909	49,481,506		69,918,966
29. Amounts receivable relating to uninsured plans, prior year					
30. Amounts receivable relating to uninsured plans, current year					
31. Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	36,515,661	36,991,635	209,606,304	5,237,820	288,351,420

DETAILS OF WRITE-IN LINES					
2501. HOME PLAN SERVICE CHARGE		8,804,210			8,804,210
2502. ADMINISTRATIVE ALLOWANCES	2,049,269	1,980,502			4,029,771
2503. MISCELLANEOUS	8,737	22,479	1,772,228		1,803,444
2598. Summary of remaining write-ins for Line 25 from overflow page	(3,315,610)	(2,921,951)		1,428,044	(4,809,517)
2599. Totals (Lines 2501 through 2503 plus 2598) (Line 25 above)	(1,257,604)	7,885,240	1,772,228	1,428,044	9,827,908

(a) Includes management fees of \$ 0 to affiliates and \$ 0 to non-affiliates.

EXHIBIT OF NET INVESTMENT INCOME

	1	2
	Collected During Year	Earned During Year
1. U.S. Government bonds	(a) 2,854,438	3,145,186
1.1 Bonds exempt from U.S. tax	(a)	
1.2 Other bonds (unaffiliated)	(a) 14,639,521	14,454,248
1.3 Bonds of affiliates	(a)	
2.1 Preferred stocks (unaffiliated)	(b) 1,262,359	1,262,359
2.11 Preferred stocks of affiliates	(b)	
2.2 Common stocks (unaffiliated)	2,124,609	2,124,888
2.21 Common stocks of affiliates		
3. Mortgage loans	(c)	
4. Real estate	(d) 3,783,986	3,783,986
5. Contract loans		
6. Cash, cash equivalents and short-term investments	(e) 1,210,500	1,210,500
7. Derivative instruments	(f)	
8. Other invested assets	48,099	48,099
9. Aggregate write-ins for investment income		(782,724)
10. Total gross investment income	25,923,512	25,246,542
11. Investment expenses		(g) 5,237,821
12. Investment taxes, licenses and fees, excluding federal income taxes		(g)
13. Interest expense		(h)
14. Depreciation on real estate and other invested assets		(i) 2,504,192
15. Aggregate write-ins for deductions from investment income		
16. Total deductions (Lines 11 through 15)		7,742,013
17. Net investment income (Line 10 minus Line 16)		17,504,529

DETAILS OF WRITE-IN LINES		
0901. INVESTMENT EXPENSES INTERNAL COSTS INVESTING AND INCOME		(385,815)
0902. PROMPT PAY INTEREST		(396,909)
0903.		
0998. Summary of remaining write-ins for Line 09 from overflow page		
0999. Totals (Lines 0901 through 0903 plus 0998) (Line 09 above)		(782,724)
1501.	NONE	
1502.		
1503.		
1598. Summary of remaining write-ins for Line 15 from overflow page		
1599. Totals (Lines 1501 through 1503 plus 1598) (Line 15 above)		

- (a) Includes \$ 805,514 accrual of discount less \$ 736,030 amortization of premium and less \$ 960,581 paid for accrued interest on purchases.
- (b) Includes \$ 0 accrual of discount less \$ 0 amortization of premium and less \$ 0 paid for accrued dividends on purchases.
- (c) Includes \$ 0 accrual of discount less \$ 0 amortization of premium and less \$ 0 paid for accrued interest on purchases.
- (d) Includes \$ 0 for company's occupancy of its own buildings; and excludes \$ 0 interest on encumbrances.
- (e) Includes \$ 0 accrual of discount less \$ 0 amortization of premium and less \$ 0 paid for accrued interest on purchases.
- (f) Includes \$ 0 accrual of discount less \$ 0 amortization of premium.
- (g) Includes \$ 0 investment expenses and \$ 0 investment taxes, licenses and fees, excluding federal income taxes, attributable to segregated and Separate Accounts.
- (h) Includes \$ 0 interest on surplus notes and \$ 0 interest on capital notes.
- (i) Includes \$ 0 depreciation on real estate and \$ 0 depreciation on other invested assets.

EXHIBIT OF CAPITAL GAINS (LOSSES)

	1	2	3	4	5
	Realized Gain (Loss) on Sales or Maturity	Other Realized Adjustments	Total Realized Capital Gain (Loss) (Columns 1 + 2)	Change in Unrealized Capital Gain (Loss)	Change in Unrealized Foreign Exchange Capital Gain (Loss)
1. U.S. Government bonds	(384,568)		(384,568)		
1.1 Bonds exempt from U.S. tax					
1.2 Other bonds (unaffiliated)	(9,235,434)		(9,235,434)	654,640	
1.3 Bonds of affiliates					
2.1 Preferred stocks (unaffiliated)	(385,662)		(385,662)	562,978	
2.11 Preferred stocks of affiliates					
2.2 Common stocks (unaffiliated)	9,389,117		9,389,117	5,117,975	
2.21 Common stocks of affiliates					
3. Mortgage loans					
4. Real estate					
5. Contract loans					
6. Cash, cash equivalents and short-term investments					
7. Derivative instruments					
8. Other invested assets				(7,785,772)	
9. Aggregate write-ins for capital gains (losses)					
10. Total capital gains (losses)	(616,547)		(616,547)	(1,450,179)	

DETAILS OF WRITE-IN LINES					
0901.	NONE				
0902.					
0903.					
0998. Summary of remaining write-ins for Line 09 from overflow page					
0999. Totals (Lines 0901 through 0903 plus 0998) (Line 09 above)					

EXHIBIT OF NONADMITTED ASSETS

	1	2	3
	Current Year Total Nonadmitted Assets	Prior Year Total Nonadmitted Assets	Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1. Bonds (Schedule D)			
2. Stocks (Schedule D):			
2.1 Preferred stocks			
2.2 Common stocks			
3. Mortgage loans on real estate (Schedule B):			
3.1 First liens			
3.2 Other than first liens			
4. Real estate (Schedule A):			
4.1 Properties occupied by the company			
4.2 Properties held for the production of income			
4.3 Properties held for sale			
5. Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)			
6. Contract loans			
7. Derivatives (Schedule DB)			
8. Other invested assets (Schedule BA)			
9. Receivables for securities			
10. Securities lending reinvested collateral assets (Schedule DL)			
11. Aggregate write-ins for invested assets			
12. Subtotals, cash and invested assets (Lines 1 to 11)			
13. Title plants (for Title insurers only)			
14. Investment income due and accrued			
15. Premiums and considerations:			
15.1 Uncollected premiums and agents' balances in the course of collection	8,617,919	5,977,817	(2,640,102)
15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			
15.3 Accrued retrospective premiums and contracts subject to redetermination			
16. Reinsurance:			
16.1 Amounts recoverable from reinsurers			
16.2 Funds held by or deposited with reinsured companies			
16.3 Other amounts receivable under reinsurance contracts			
17. Amounts receivable relating to uninsured plans	1,765,090	2,901,687	1,136,597
18.1 Current federal and foreign income tax recoverable and interest thereon			
18.2 Net deferred tax asset			
19. Guaranty funds receivable or on deposit			
20. Electronic data processing equipment and software	37,679,384	37,429,574	(249,810)
21. Furniture and equipment, including health care delivery assets	418,285	460,747	42,462
22. Net adjustment in assets and liabilities due to foreign exchange rates			
23. Receivables from parent, subsidiaries and affiliates			
24. Health care and other amounts receivable	581,413	3,101,350	2,519,937
25. Aggregate write-ins for other-than-invested assets	26,611,887	39,250,064	12,638,177
26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	75,673,978	89,121,239	13,447,261
27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts			
28. Total (Lines 26 and 27)	75,673,978	89,121,239	13,447,261

DETAILS OF WRITE-IN LINES			
1101.	NONE		
1102.			
1103.			
1198. Summary of remaining write-ins for Line 11 from overflow page			
1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above)			
2501. PREPAID EXPENSES	23,629,128	34,867,325	11,238,197
2502. LEASEHOLD IMPROVEMENTS	2,275,425	2,590,359	314,934
2503. OTHER RECEIVABLES	496,615	1,547,041	1,050,426
2598. Summary of remaining write-ins for Line 25 from overflow page	210,719	245,339	34,620
2599. Totals (Lines 2501 through 2503 plus 2598) (Line 25 above)	26,611,887	39,250,064	12,638,177

EXHIBIT 1 – ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

Source of Enrollment	Total Members at End of					6 Current Year Member Months
	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	
1. Health Maintenance Organizations						
2. Provider Service Organizations						
3. Preferred Provider Organizations	216,195	214,403	215,378	216,062	215,864	2,583,057
4. Point of Service						
5. Indemnity Only	569	549	504	489	482	6,164
6. Aggregate write-ins for other lines of business	171,742	172,612	173,496	173,218	172,335	2,069,972
7. Total	388,506	387,564	389,378	389,769	388,681	4,659,193

DETAILS OF WRITE-IN LINES						
0601. DENTAL ONLY	74,605	76,936	77,652	77,497	77,923	925,043
0602. STOP LOSS	46,336	45,094	45,025	45,687	44,470	541,315
0603. MEDICARE SUPPLEMENT	21,786	21,482	21,386	21,316	21,075	256,181
0698. Summary of remaining write-ins for Line 06 from overflow page	29,015	29,100	29,433	28,718	28,867	347,433
0699. Totals (Lines 0601 through 0603 plus 0698) (Line 06 above)	171,742	172,612	173,496	173,218	172,335	2,069,972

NOTES TO FINANCIAL STATEMENTS

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

(1) The Annual Statement has been completed in accordance with the NAIC Accounting Practices and Procedures manual and as prescribed by the State of Rhode Island Department of Business Regulation – Insurance Division.

(2) The Plan's 2024 Annual Statement excludes Administrative Service Contract (ASC) business from revenue, and medical and hospital claims. The ASC reimbursement has been classified as a reduction to claims adjustment and general administrative expenses.

A reconciliation of the Plan's net income and capital surplus between NAIC SAP and practices prescribed and permitted by the State of RI is shown below:

	SSAP #	F/S Page	F/S Line #	2024	2023
Net Income					
(1) State basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$ (115,018,392)	\$ 601,743
(2) State prescribed practices that are an increase / (decrease) from NAIC SAP:					
(3) State permitted practices that are an increase / (decrease) from NAIC SAP:					
(4) NAIC SAP (1-2-3=4)	XXX	XXX	XXX	<u>\$ (115,018,392)</u>	<u>\$ 601,743</u>
Surplus					
(5) State basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$ 337,171,513	\$ 439,548,497
(6) State prescribed practices that are an increase / (decrease) from NAIC SAP:					
(7) State permitted practices that are an increase / (decrease) from NAIC SAP:					
(8) NAIC SAP (5-6-7=8)	XXX	XXX	XXX	<u>\$ 337,171,513</u>	<u>\$ 439,548,497</u>

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of the financial statements in conformity with Statutory Accounting Principles requires management to make estimates and assumptions that effect the reported amounts of assets and liabilities. It also requires disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates.

C. Accounting Policy

- (1) Short-term investments are stated at amortized cost.
- (2) Bonds not backed by other loans are stated at amortized cost using the effective interest rate method.
- (3) Common stocks at fair market value except the investments in stocks of uncombined subsidiaries and affiliates in which the Plan has an interest of 20% or more are carried on the equity basis.
- (4) Preferred stock is stated in accordance with guidance provided in SSAP No. 32.
- (5) The Plan does not have mortgage loans on real estate.
- (6) Loan-backed securities are stated at either amortized cost or the lower of amortized cost or fair market value. The prospective adjustment method is used to value all securities except for interest only securities or securities where the yield had become negative.
- (7) The Plan has a minority interest in International Blue Solutions, LLC with a carrying value of \$1,428,566. The Plan also has a minority interest in Blue Health Intelligence Co, LLC of \$1,295,188. The Plan also has a minority interest in Prime Therapeutics of \$26,988,772. The Plan also has a minority interest in Oak Street Health-RI, LLC of \$0. The Plan also has a minority interest in BCBS Venture Partners, LLC of \$2,041,186. The Plan also has a minority interest in BCBS Venture V, LLC of \$544,215.
- (8) The Plan has minor ownership interests in partnerships and limited liability companies. The value of these interests are based on the underlying audited GAAP equity of the investee.
- (9) The Plan does not own derivative investments.
- (10) The Plan considers anticipated investment income as a factor in premium deficiency calculation.
- (11) Unpaid losses and loss adjustment expenses include an amount determined from individual case estimates and loss reports and an amount, based on past experience, for losses incurred but not reported. Such liabilities are necessarily based on assumptions and estimates and while management believes the amount is adequate, the ultimate liability may be in excess of or less than the amount provided. The methods for making such estimates and for establishing the resulting liability are continually reviewed and any adjustments are reflected in the period determined.
- (12) The Plan has not modified its capitalization policy from the prior period.
- (13) The Plan's pharmacy benefit manager provides estimated pharmacy rebates on a quarterly basis.

D. Going Concern

Management continually evaluates the Plan's ability to continue as a going concern. After considering management's plans, potential events and principal conditions, there is no substantial doubt about the Plan's ability to continue as a going concern.

2. Accounting Changes and Corrections of Errors

There were no Accounting Changes and Correction of Errors in 2024.

3. Business Combinations and Goodwill

There were no Business Combinations and resulting Goodwill in 2024.

NOTES TO FINANCIAL STATEMENTS

3. Business Combinations and Goodwill (Continued)

- A. Statutory Purchase Method - Not Applicable
- B. Statutory Merger - Not Applicable
- C. Assumption Reinsurance - Not Applicable
- D. Impairment Loss - Not Applicable
- E. Subcomponents and Calculation of Adjusted Surplus and Total Admitted Goodwill - Not Applicable

4. Discontinued Operations

- The Plan did not incur discontinued operations for 2024.
- A. Discontinued Operation Disposed of or Classified as Held for Sale - Not Applicable
 - B. Change in Plan of Sale of Discontinued Operation - Not Applicable
 - C. Nature of Any Significant Continuing Involvement with Discontinued Operations After Disposal - Not Applicable
 - D. Equity Interest Retained in the Discontinued Operation After Disposal - Not Applicable

5. Investments

- A. Mortgage Loans, including Mezzanine Real Estate Loans

The Plan did not have any outstanding mortgage loans in 2024.

 - (1) Maximum and minimum lending rates for mortgage loans - Not Applicable
 - (2) Maximum percentage of any one loan to the value of security - Not Applicable
 - (3) Taxes, assessments and any amounts advanced and not included in mortgage loan total - Not Applicable
 - (4) Age analysis of mortgage loans and identification of mortgage loans in which the insurer is a participant or co-lender in a mortgage loan agreement - Not Applicable
 - (5) Investment in impaired loans with or without allowance for credit losses and impaired loans subject to a participant or co-lender mortgage loan agreement for which the reporting entity is restricted from unilaterally foreclosing on the mortgage loan - Not Applicable
 - (6) Investment in impaired loans - average recorded investment, interest income recognized, recorded investment on nonaccrual status and amount of interest income recognized using a cash-basis method of accounting - Not Applicable
 - (7) Allowance for credit losses - Not Applicable
 - (8) Mortgage loans derecognized as a result of foreclosure - Not Applicable
 - (9) Policy for recognizing interest income and impaired loans - Not Applicable
- B. Debt Restructuring

The Plan did not have any debt restructuring in 2024.
- C. Reverse Mortgages

The Plan did not have any reverse mortgages in 2024.

 - (1) Accounting policies and methods - Not Applicable
 - (2) Commitment under agreement - Not Applicable
 - (3) Reserve netted against reverse mortgage assets - Not Applicable
 - (4) Investment income or loss recognized as a result of re-estimated cash flows - Not Applicable
- D. Loan-Backed Securities
 - (1) The Plan utilizes the prospective method for loan backed securities. The Plan obtains the prepayment assumptions for mortgage-backed/asset-backed securities from the following hierarchy: Bloomberg median speed; if none, then 6 month historical CPR; if none, then YieldBook prepayment model that runs fixed rate MBS at 100% of the model and Hybrid Arms at 100% of MTB (Model to Balloon). CMBS are run at a 0% constant prepayment rate. If this information is not obtainable from one of these sources then analysts determine the cash flows to be used. The Plan utilizes the fair market value as published by the NAIC Valuation Securities Manual. If the rate is not published by the Securities Valuation Office (SVO), the security is carried at amortized value in accordance with NAIC guidelines.
 - (2) Loan-backed and structured securities with a recognized other-than-temporary impairment (OTTI)

The Plan did not recognize other-than-temporary impairment (OTTI) for loan-backed securities:

NOTES TO FINANCIAL STATEMENTS

5. Investments (Continued)

	(1)	(2)	(3)
	Amortized Cost Basis Before Other- Than-Temporary Impairment	Other-Than- Temporary Impairment Recognized in Loss	Fair Value (1 - 2)
OTTI Recognized 1st Quarter			
a. Intent to sell	\$	\$	\$
b. Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis			
c. Total 1st Quarter (a+b)	\$	\$	\$
OTTI Recognized 2nd Quarter			
d. Intent to sell	\$	\$	\$
e. Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis			
f. Total 2nd Quarter (d+e)	\$	\$	\$
OTTI Recognized 3rd Quarter			
g. Intent to sell	\$	\$	\$
h. Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis			
i. Total 3rd Quarter (g+h)	\$	\$	\$
OTTI Recognized 4th Quarter			
j. Intent to sell	\$	\$	\$
k. Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis			
l. Total 4th Quarter (j+k)	\$	\$	\$
m. Annual aggregate total (c+f+i+l)		\$	

(3) Securities held that were other-than-temporarily impaired due to the present value of cash flows expected to be collected was less than the amortized cost of securities

The Plan did not recognize OTTI for loan-backed securities see table below:

(1)	(2)	(3)	(4)	(5)	(6)	(7)
CUSIP	Book/Adjusted Carrying Value Amortized Cost Before Current Period OTTI	Present Value of Projected Cash Flows	Recognized OTTI	Amortized Cost After OTTI	Fair Value at Time of OTTI	Date of Financial Statement Where Reported
Total			\$			

(4) All impaired securities for which an OTTI has not been recognized in earnings as a realized loss

Loan-backed securities with unrealized losses as of December 31, 2024:

a. The aggregate amount of unrealized losses:	
1. Less than 12 months	\$ 1,372,971
2. 12 months or longer	12,409,750
b. The aggregate related fair value of securities with unrealized losses:	
1. Less than 12 months	\$ 69,871,060
2. 12 months or longer	68,883,370

(5) The evaluation of impairments is a quantitative and qualitative process, which is subject to risks and uncertainties and is intended to determine whether declines in the fair value of investments should be recognized in the current period. The risks and uncertainties include changes in general economic conditions, the issuer's financial condition or near term recovery prospects, the effects of changes in interest rates or credit spreads and the recovery period. As of December 31, 2024, the Plan does not consider loan-backed securities in an unrealized loss position to be other-than-temporarily impaired as reported in the table above.

E. Dollar Repurchase Agreements and/or Securities Lending Transactions

- (1) For repurchase agreements, the Plan ensures that the fair market value of the collateralized security is equal to or exceeds the amount under agreement to repurchase.
- (2) The Plan has investments pledged as collateral. The securities are US Treasury Bonds, Corporate Bonds and Equity with a carrying value of \$229,580,298.
- (3) Collateral received
The Plan has not accepted any collateral.
(a) Aggregate amount collateral received - Not Applicable
(b) Fair value and portion sold or repledged
The Plan has not accepted any collateral.

The fair value of that collateral and of the portion of that collateral that it has sold or repledged \$ -

NOTES TO FINANCIAL STATEMENTS

5. Investments (Continued)

(c) Sources and uses of collateral - Not Applicable

(4) The Plan does not have any securities lending transactions.

(5) Collateral reinvestment

The Plan does not have any collateral reinvestment.

(6) The Plan has not accepted any collateral.

(7) Collateral for securities lending transactions that extend beyond one year from the reporting date

The Plan does not have any securities lending transactions.

F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

Repurchase Transaction - Cash Taker - Overview of Secured Borrowing Transactions

Repurchase agreements accounted for as secured borrowing is not applicable.

(1) Information regarding the company policy or strategies for engaging in repo programs, policy for requiring collateral - Not Applicable

(2) Type of repo trades used - Not Applicable

(3) Original (flow) & residual maturity - Not Applicable

(4) Fair value of securities sold and/or acquired that resulted in default - Not Applicable

(5) Securities "sold" under repo - secured borrowing - Not Applicable

(6) Securities sold under repo - secured borrowing by NAIC designation - Not Applicable

(7) Collateral received - secured borrowing - Not Applicable

(8) Cash & non-cash collateral received - secured borrowing by NAIC designation - Not Applicable

(9) Allocation of aggregate collateral by remaining contractual maturity - Not Applicable

(10) Allocation of aggregate collateral reinvested by remaining contractual maturity - Not Applicable

(11) Liability to return collateral - secured borrowing (total) - Not Applicable

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

Repurchase Transaction - Cash Provider - Overview of Secured Borrowing Transactions

Reverse repurchase agreements accounted for as secured borrowing is not applicable.

(1) Information regarding the company policy or strategies for engaging in repo programs, policy for requiring collateral - Not Applicable

(2) Type of repo trades used - Not Applicable

(3) Original (flow) & residual maturity - Not Applicable

(4) Fair value of securities sold and/or acquired that resulted in default - Not Applicable

(5) Fair value of securities acquired under repo - secured borrowing - Not Applicable

(6) Securities acquired under repo - secured borrowing by NAIC designation - Not Applicable

(7) Collateral provided - secured borrowing - Not Applicable

(8) Allocation of aggregate collateral pledged by remaining contractual maturity - Not Applicable

(9) Recognized receivable for return of collateral - secured borrowing - Not Applicable

(10) Recognized liability to return collateral - secured borrowing (total) - Not Applicable

H. Repurchase Agreements Transactions Accounted for as a Sale

Repurchase Transaction - Cash Taker - Overview of Sale Transactions

Repurchase agreements accounted for as a sale is not applicable.

(1) Information regarding the company policy or strategies for engaging in repo programs and policy for requiring collateral - Not Applicable

(2) Type of repo trades used - Not Applicable

(3) Original (flow) & residual maturity - Not Applicable

(4) Fair value of securities sold and/or acquired that resulted in default - Not Applicable

(5) Securities "sold" under repo - sale - Not Applicable

(6) Securities sold under repo - sale by NAIC designation - Not Applicable

(7) Proceeds received - sale - Not Applicable

(8) Cash & non-cash collateral received - sale by NAIC designation - Not Applicable

(9) Recognized forward resale commitment - Not Applicable

NOTES TO FINANCIAL STATEMENTS

5. Investments (Continued)

I. Reverse Repurchase Agreements Transactions Accounted for as a Sale

Repurchase Transaction - Cash Provider - Overview of Sale Transactions

Reverse repurchase agreements accounted for as sale is not applicable.

- (1) Information regarding the company policy or strategies for engaging in repo programs, policy for requiring collateral - Not Applicable
- (2) Type of repo trades used - Not Applicable
- (3) Original (flow) & residual maturity - Not Applicable
- (4) Fair value of securities sold and/or acquired that resulted in default - Not Applicable
- (5) Securities acquired under repo - sale - Not Applicable
- (6) Securities acquired under repo - sale by NAIC designation - Not Applicable
- (7) Proceeds provided - sale - Not Applicable
- (8) Recognized forward resale commitment - Not Applicable

J. Real Estate

The Plan does not hold real estate for investment purposes.

- (1) Impairment loss - Not Applicable
- (2) Real estate sold or classified held for sale - Not Applicable
- (3) Changes to a plan of sale for an investment in real estate - Not Applicable
- (4) Retail land sales operations - Not Applicable
- (5) Participating mortgage loan features - Not Applicable

K. Low-Income Housing Tax Credits (LIHTC)

The Plan does not have any low-income housing credits.

- (1) Remaining years of unexpired tax credits - Not Applicable
- (2) Amount of LIHTC and other tax benefits - Not Applicable
- (3) Balance of investment recognized - Not Applicable
- (4) Regulatory reviews - Not Applicable
- (5) Significance of an investment - Not Applicable
- (6) Impaired assets - Not Applicable
- (7) Write-downs and reclassifications - Not Applicable

L. Restricted Assets

- (1) Restricted assets (including pledged)

	(1)	(2)	(3)	(4)	(5)	(6)	(7)
Restricted Asset Category	Total Gross (Admitted & Nonadmitted) Restricted from Current Year	Total Gross (Admitted & Nonadmitted) Restricted From Prior Year	Increase / (Decrease) (1 - 2)	Total Current Year Nonadmitted Restricted	Total Current Year Admitted Restricted (1 - 4)	Gross (Admitted & Nonadmitted) Restricted to Total Assets	Admitted Restricted to Total Admitted Assets
a. Subject to contractual obligation for which liability is not shown	\$... 43,040,000	\$... 35,958,000	\$... 7,082,000	\$.....	\$... 43,040,000 3.937 % 4.229 %
b. Collateral held under security lending agreements							
c. Subject to repurchase agreements	84,398	57,582	26,816		84,398 0.008 0.008
d. Subject to reverse repurchase agreements							
e. Subject to dollar repurchase agreements							
f. Subject to dollar reverse repurchase agreements							
g. Placed under option contracts							
h. Letter stock or securities restricted as to sale - excluding FHLB capital stock							
i. FHLB capital stock	4,672,900	3,261,400	1,411,500		4,672,900 0.427 0.459
j. On deposit with states							
k. On deposit with other regulatory bodies							
l. Pledged as collateral to FHLB (including assets backing funding agreements)	181,783,000	171,821,623	9,961,377		181,783,000 16.627 17.864
m. Pledged as collateral not captured in other categories							
n. Other restricted assets							
o. Total restricted assets (Sum of a through n)	<u>\$... 229,580,298</u>	<u>\$... 211,098,605</u>	<u>\$... 18,481,693</u>	<u>\$.....</u>	<u>\$... 229,580,298</u>	<u>..... 20.999 %</u>	<u>..... 22.560 %</u>

- (2) Detail of assets pledged as collateral not captured in other categories (contracts that share similar characteristics, such as reinsurance and derivatives, are reported in the aggregate)

Pledged Assets not captured in other categories is not applicable to the Plan.

- (3) Detail of other restricted assets (contracts that share similar characteristics, such as reinsurance and derivatives, are reported in the aggregate)

Other Restricted Assets is not applicable to the Plan.

NOTES TO FINANCIAL STATEMENTS

5. Investments (Continued)

(4) Collateral received and reflected as assets within the reporting entity's financial statements
The Plan does not have any Collateral received in Assets.

M. Working Capital Finance Investments

The Plan does not have any Working Capital Finance Investments.

(1) Aggregate working capital finance investments (WCFI) book/adjusted carrying value by NAIC designation - Not Applicable

(2) Aggregate maturity distribution on the underlying working capital finance programs - Not Applicable

(3) Events of default of working capital finance investments during the reporting period - Not Applicable

N. Offsetting and Netting of Assets and Liabilities

The Plan does not offset Assets and Liabilities of Investments.

O. 5GI Securities

The Plan does not own only 5GI* Securities.

P. Short Sales

The Plan does not have any short sales.

(1) Unsettled short sale transactions (outstanding as of reporting date) - Not Applicable

(2) Settled short sale transactions - Not Applicable

Q. Prepayment Penalty and Acceleration Fees

The Plan did not have any prepayment and acceleration fees in 2024.

	General Account
(1) Number of CUSIPs	—
(2) Aggregate amount of investment income	\$ —

R. Reporting Entity's Share of Cash Pool by Asset Type

Asset Type	Percent Share
(1) Cash	1,817.800 %
(2) Cash Equivalents	(1,717.800)%
(3) Short-Term Investments	%
(4) Total (Must Equal 100%)	100.000 %

S. Aggregate Collateral Loans by Qualifying Investment Collateral

The Plan did not have any aggregate collateral loans by qualifying investment collateral.

NOTES TO FINANCIAL STATEMENTS

5. Investments (Continued)

	Collateral Type	Aggregate Collateral Loan	Admitted	Nonadmitted
(1)	Cash, Cash Equivalent & ST Investments			
	a. Affiliated	\$	\$	\$
	b. Unaffiliated			
(2)	Bonds			
	a. Affiliated			
	b. Unaffiliated			
(3)	Loan-Backed and Structured Securities			
	a. Affiliated			
	b. Unaffiliated			
(4)	Preferred Stocks			
	a. Affiliated			
	b. Unaffiliated			
(5)	Common Stocks			
	a. Affiliated			
	b. Unaffiliated			
(6)	Real Estate			
	a. Affiliated			
	b. Unaffiliated			
(7)	Mortgage Loans			
	a. Affiliated			
	b. Unaffiliated			
(8)	Joint Ventures, Partnerships, LLC			
	a. Affiliated			
	b. Unaffiliated			
(9)	Other Qualifying Investments			
	a. Affiliated			
	b. Unaffiliated			
(10)	Collateral Does not Qualify as an Investment			
	a. Affiliated			
	b. Unaffiliated			
(11)	Total	\$	\$	\$

6. Joint Ventures, Partnerships and Limited Liability Companies

- A. Investments in Joint Ventures, Partnerships or Limited Liability Companies that Exceed 10% of Admitted Assets
The Plan does not have an investment interest in joint ventures, partnerships and limited liability companies that individually exceeds 10% of its admitted assets.
- B. Impaired Investments in Joint Ventures, Partnerships and Limited Liability Companies - Not Applicable

7. Investment Income

- A. Due and Accrued Income Excluded from Surplus
The Plan has not excluded from assigned funds (surplus) any investment income due and accrued.
- B. Total Amount Excluded - Not Applicable
- C. The gross, nonadmitted and admitted amounts for interest income due and accrued

	Interest Income Due and Accrued	Amount
1. Gross		\$ 3,280,935
2. Nonadmitted		\$
3. Admitted		\$ 3,280,935

- D. The aggregate deferred interest - Not Applicable
- E. The cumulative amounts of paid-in-kind (PIK) interest included in the current principal balance - Not Applicable

8. Derivative Instruments

- The Plan does not own any derivative instruments.
- A. Derivatives under SSAP No. 86 - Derivatives - Not Applicable
- B. Derivatives under SSAP No. 108 - Derivative Hedging Variable Annuity Guarantees (Life/Fraternal Only) - Not Applicable

9. Income Taxes

The Inflation Reduction Act created the Corporate Alternative Minimum Tax (CAMT), which imposes a 15% minimum tax on the adjusted financial statement income of large corporations for taxable years beginning after December 31, 2022. The CAMT generally applies to large corporations with average annual financial statement income exceeding \$1.0 billion. Given the \$1.0 billion dollar threshold, BCBSRI will not be subject to the CAMT.

NOTES TO FINANCIAL STATEMENTS

9. Income Taxes (Continued)

A. Components of the Net Deferred Tax Asset/(Liability)

(1) Change between years by tax character

	2024			2023			Change		
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
	Ordinary	Capital	Total (Col 1+2)	Ordinary	Capital	Total (Col 4+5)	Ordinary (Col 1-4)	Capital (Col 2-5)	Total (Col 7+8)
(a) Gross deferred tax assets	\$ 71,823,373	\$ 1,666,797	\$ 73,490,170	\$ 48,023,489	\$ 1,551,087	\$ 49,574,576	\$ 23,799,884	\$ 115,710	\$ 23,915,594
(b) Statutory valuation allowance adjustments	63,578,597	1,666,797	65,245,394	39,372,265	1,551,087	40,923,352	24,206,332	115,710	24,322,042
(c) Adjusted gross deferred tax assets (1a - 1b)	8,244,776	-	8,244,776	8,651,224	-	8,651,224	(406,448)	-	(406,448)
(d) Deferred tax assets nonadmitted									
(e) Subtotal net admitted deferred tax asset (1c - 1d)	\$ 8,244,776	\$ -	\$ 8,244,776	\$ 8,651,224	\$ -	\$ 8,651,224	\$ (406,448)	\$ -	\$ (406,448)
(f) Deferred tax liabilities	1,116,400	7,128,376	8,244,776	689,128	7,962,096	8,651,224	427,272	(833,720)	(406,448)
(g) Net admitted deferred tax asset/(net deferred tax liability) (1e - 1f)	\$ 7,128,376	\$ (7,128,376)	\$ -	\$ 7,962,096	\$ (7,962,096)	\$ -	\$ (833,720)	\$ 833,720	\$ -

(2) Admission calculation components SSAP No. 101

	2024			2023			Change		
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
	Ordinary	Capital	Total (Col 1+2)	Ordinary	Capital	Total (Col 4+5)	Ordinary (Col 1-4)	Capital (Col 2-5)	Total (Col 7+8)
(a) Federal income taxes paid in prior years recoverable through loss carrybacks	\$	\$	\$	\$	\$	\$	\$	\$	\$
(b) Adjusted gross deferred tax assets expected to be realized (excluding the amount of deferred tax assets from 2(a) above) after application of the threshold limitation (lesser of 2(b)1 and 2(b)2 below)	7,128,376	(7,128,376)	-	7,962,096	(7,962,096)	-	(833,720)	833,720	-
1. Adjusted gross deferred tax assets expected to be realized following the balance sheet date									
2. Adjusted gross deferred tax assets allowed per limitation threshold	XXX	XXX		XXX	XXX		XXX	XXX	
(c) Adjusted gross deferred tax assets (excluding the amount of deferred tax assets from 2(a) and 2(b) above) offset by gross deferred tax liabilities									
(d) Deferred tax assets admitted as the result of application of SSAP No. 101.									
Total (2(a) + 2(b) + 2(c))	\$ 7,128,376	\$ (7,128,376)	\$ -	\$ 7,962,096	\$ (7,962,096)	\$ -	\$ (833,720)	\$ 833,720	\$ -

(3) Ratio used as basis of admissibility

	2024	2023
(a) Ratio percentage used to determine recovery period and threshold limitation amount	473.900 %	656.200 %
(b) Amount of adjusted capital and surplus used to determine recovery period and threshold limitation in 2(b)2 above	\$ 65,088,225	\$ 65,924,862

(4) Impact of tax-planning strategies

(a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage

	2024		2023		Change	
	(1)	(2)	(3)	(4)	(5)	(6)
	Ordinary	Capital	Ordinary	Capital	Ordinary (Col. 1-3)	Capital (Col. 2-4)
1. Adjusted gross DTAs amount from Note 9A1(c)	\$ 8,244,776	\$ -	\$ 8,651,224	\$ -	\$ (406,448)	\$ -
2. Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies	%	%	%	%	%	%
3. Net admitted adjusted gross DTAs amount from Note 9A1(e)	\$ 8,244,776	\$ -	\$ 8,651,224	\$ -	\$ (406,448)	\$ -
4. Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies	%	%	%	%	%	%

(b) Use of reinsurance-related tax-planning strategies

Does the company's tax-planning strategies include the use of reinsurance? NO

B. Regarding Deferred Tax Liabilities That Are Not Recognized - Not Applicable

NOTES TO FINANCIAL STATEMENTS

9. Income Taxes (Continued)

C. Major Components of Current Income Taxes Incurred

Current income taxes incurred consist of the following major components:			
	(1) 2024	(2) 2023	(3) Change (1-2)
1. Current Income Tax			
(a) Federal	\$	\$	\$
(b) Foreign			
(c) Subtotal (1a+1b)	\$	\$	\$
(d) Federal income tax on net capital gains			
(e) Utilization of capital loss carry-forwards			
(f) Other			
(g) Federal and foreign income taxes incurred (1c+1d+1e+1f)	\$	\$	\$
	(1) 2024	(2) 2023	(3) Change (1-2)
2. Deferred Tax Assets			
(a) Ordinary			
(1) Discounting of unpaid losses	\$ 781,253	\$ 729,355	\$ 51,898
(2) Unearned premium reserve			
(3) Policyholder reserves			
(4) Investments			
(5) Deferred acquisition costs	5,133,000	5,137,421	(4,421)
(6) Policyholder dividends accrual			
(7) Fixed assets	3,596,927	3,604,060	(7,133)
(8) Compensation and benefits accrual	5,076,735	2,266,819	2,809,916
(9) Pension accrual			
(10) Receivables - nonadmitted	641,306	1,637,038	(995,732)
(11) Net operating loss carry-forward	32,526,024	15,191,285	17,334,739
(12) Tax credit carry-forward			
(13) Other	24,068,128	19,457,511	4,610,617
(99) Subtotal (Sum of 2a1 through 2a13)	\$ 71,823,373	\$ 48,023,489	\$ 23,799,884
(b) Statutory valuation allowance adjustment	63,578,597	39,372,265	24,206,332
(c) Nonadmitted			
(d) Admitted ordinary deferred tax assets (2a99 - 2b - 2c)	\$ 8,244,776	\$ 8,651,224	\$ (406,448)
(e) Capital			
(1) Investments	\$	\$	\$
(2) Net capital loss carry-forward	1,666,797	1,551,087	115,710
(3) Real estate			
(4) Other			
(99) Subtotal (2e1+2e2+2e3+2e4)	\$ 1,666,797	\$ 1,551,087	\$ 115,710
(f) Statutory valuation allowance adjustment	1,666,797	1,551,087	115,710
(g) Nonadmitted			
(h) Admitted capital deferred tax assets (2e99 - 2f - 2g)	-	-	-
(i) Admitted deferred tax assets (2d + 2h)	\$ 8,244,776	\$ 8,651,224	\$ (406,448)
	(1) 2024	(2) 2023	(3) Change (1-2)
3. Deferred Tax Liabilities			
(a) Ordinary			
(1) Investments	\$	\$	\$
(2) Fixed assets			
(3) Deferred and uncollected premium			
(4) Policyholder reserves			
(5) Other	1,116,400	689,128	427,272
(99) Subtotal (3a1+3a2+3a3+3a4+3a5)	\$ 1,116,400	\$ 689,128	\$ 427,272
(b) Capital			
(1) Investments	\$ 7,128,376	\$ 7,962,096	\$ (833,720)
(2) Real estate			
(3) Other			
(99) Subtotal (3b1+3b2+3b3)	\$ 7,128,376	\$ 7,962,096	\$ (833,720)
(c) Deferred tax liabilities (3a99 + 3b99)	\$ 8,244,776	\$ 8,651,224	\$ (406,448)
4. Net deferred tax assets/liabilities (2i - 3c)	\$ -	\$ -	\$ -

NOTES TO FINANCIAL STATEMENTS

9. Income Taxes (Continued)

D. Among the More Significant Book to Tax Adjustments

The provision for federal income taxes incurred is different from that which would be obtained by applying the statutory federal income tax rate to income taxes including realized capital gains/losses. The significant items causing this difference are as follows:

	2024	Effective Tax Rate
Income before Taxes (including all realized capital gains/losses)	\$ (24,153,862)	21.000 %
Health Insurer fee		
Special 3 month reserve deduction		
Change in Unrealized gains/losses	(169,229)	0.147 %
Revisions to estimates	(3,928,472)	3.416 %
Statutory Valuation Allowance Adjustment	24,322,041	-21.146 %
Permanent differences	1,038,517	-0.903 %
Change in non-admitted assets	2,823,924	-2.455 %
Other	67,081	-0.058 %
Total	\$ -	- %
	2024	Effective Tax Rate
Federal Income Taxes Incurred	\$	%
Change in net deferred income taxes		
Total statutory income taxes	\$	%

E. Operating Loss and Tax Credit Carryforwards

(1) Carryforwards, recoverable taxes, and IRC 6603 deposits

Plan has net operating loss carryforwards of \$154,900,114 expiring through calendar years 2032 to 2044.

Plan has contribution carryforwards of \$7,260,298 expiring in calendar year 2026 to 2029.

Plan has capital loss carryforwards of \$7,937,130 expiring in calendar year 2027 to 2029.

(2) Income tax expense available for recoupment

The Plan has no income taxes incurred in the current and prior years that will be available for recoupment in the event of future net losses.

(3) Deposits admitted under IRS Code Section 6603 - Not Applicable

F. Consolidated Federal Income Tax Return

(1) The Plan does not join in the filing of a consolidated federal income tax return.

(2) Method of allocation - Not Applicable

G. Federal or Foreign Income Tax Loss Contingencies

The Plan has not recorded any contingencies related to taxes.

H. Repatriation Transition Tax (RTT) - Not Applicable

I. Alternative Minimum Tax (AMT) Credit - Not Applicable

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

A. See Schedule Y Part 1 for nature of relationship.

B. BCBSRI made an initial investment in OSH-RI, LLC on November 20, 2018 of \$3,493,000. BCBSRI did not make additional contributions in OSH-RI, LLC for the periods ended December 31, 2024 and 2023 of \$0 and \$0, respectively. BCBSRI current carrying value as of December 31, 2024 in OSH-RI, LLC is \$0.

C. Transactions With Related Party Who Are Not Reported on Schedule Y - Not Applicable

D. Amounts Due To or From Related Parties - Not Applicable

E. Management Service Contracts and Cost Sharing Arrangements - Not Applicable

F. Guarantees or Contingencies - Not Applicable

G. Nature of Relationships that Could Affect Operations - Not Applicable

H. Amount Deducted for Investment in Upstream Company - Not Applicable

I. Detail of Investments in Affiliates Greater Than 10% of Admitted Assets - Not Applicable

J. Write-Down for Impairments of Investments in Subsidiary Controlled or Affiliated Companies - Not Applicable

K. Foreign Subsidiary Value Using CARVM - Not Applicable

L. Downstream Holding Company Value Using Look-Through Method - Not Applicable

M. All SCA Investments - Not Applicable

N. Investment in Insurance SCAs - Not Applicable

NOTES TO FINANCIAL STATEMENTS

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties (Continued)

O. SCA and SSAP No. 48 Entity Loss Tracking

	(1)	(2)	(3)	(4)	(5)	(6)
					Guaranteed Obligation / Commitment for	Amount of the Recognized
Entity	Reporting Entity's Share of Net Income (Loss)	Accumulated Share of Net Income (Losses)	Reporting Entity's Share of Equity, Including Negative Equity		Financial Support (Yes / No)	Guarantee Under SSAP No. 5R
OSH-RI, LLC	\$ (3,080,327)	\$ (3,080,327)	\$ (3,080,327)		NO	\$ -

11. Debt

A. Mortgage on Building

- (1) Date issued is January 14, 2008.
- (2) Bank loan for corporate office building.
- (3) The maximum loan amount is \$90,000,000.
- (4) Carrying value of loan is \$33,246,679.
- (5) The rate at which interest accrues is 30-day LIBOR plus an agreed upon spread (basis points).
- (6) The effective interest rate is equivalent to the 30-day LIBOR plus an agreed upon spread (basis points).
- (7) Office building structure.
- (8) Interest paid year to date is \$2,076,427.
- (9) Loan converted to fixed rate mortgage instrument in February 2010.
- (10) Not Applicable
- (11) Not Applicable
- (12) Not Applicable

B. FHLB (Federal Home Loan Bank) Agreements

- (1) The Plan is a member of the Federal Home Loan Bank (FHLB) of Boston. Through its membership, the Plan has conducted business activity with FHLB. It is part of the Plan's strategy to utilize these funds as backup liquidity if necessary. The Plan has determined the actual maximum borrowing capacity as \$130,000,000. The Plan has calculated this amount with approval from the Plan's Board of Directors.
- (2) FHLB capital stock
- (a) Aggregate totals

	Total
1. Current Year	
(a) Membership stock - Class A	\$
(b) Membership stock - Class B	512,900
(c) Activity stock	4,160,000
(d) Excess stock	
(e) Aggregate total (a+b+c+d)	\$ 4,672,900
(f) Actual or estimated borrowing capacity as determined by the insurer	\$ 130,000,000
2. Prior Year-End	
(a) Membership stock - Class A	\$
(b) Membership stock - Class B	461,400
(c) Activity stock	2,800,000
(d) Excess stock	
(e) Aggregate total (a+b+c+d)	\$ 3,261,400
(f) Actual or estimated borrowing capacity as determined by the insurer	\$ 130,000,000
(b) Membership stock (Class A and B) eligible and not eligible for redemption	

	(1)	(2)	Eligible for Redemption			
Membership Stock	Current Year Total (2+3+4+5+6)	Not Eligible for Redemption	(3) Less Than 6 Months	(4) 6 Months to Less Than 1 Year	(5) 1 to Less Than 3 Years	(6) 3 to 5 Years
1. Class A	\$	\$	\$	\$	\$	\$
2. Class B	\$ 512,900	\$ 512,900	\$	\$	\$	\$

NOTES TO FINANCIAL STATEMENTS

11. Debt (Continued)

(3) Collateral pledged to FHLB

(a) Amount pledged as of reporting date

	(1)	(2)	(3)
	Fair Value	Carrying Value	Aggregate Total Borrowing
1. Current year total collateral pledged	\$ 166,730,949	\$ 181,752,999	\$ 104,000,000
2. Prior year-end total collateral pledged	160,360,195	171,821,623	70,000,000

(b) Maximum amount pledged during reporting period

	(1)	(2)	(3)
	Fair Value	Carrying Value	Amount Borrowed at Time of Maximum Collateral
1. Current year total maximum collateral pledged	\$ 166,730,949	\$ 181,752,999	\$ 104,000,000
2. Prior year-end total maximum collateral pledged	160,360,195	171,821,623	70,000,000

(4) Borrowing from FHLB

(a) Amount as of the reporting date

	Total	Funding Agreements Reserves Established
1. Current Year		
(a) Debt	\$ 104,000,000	XXX
(b) Funding agreements		\$
(c) Other		XXX
(d) Aggregate total (a+b+c)	\$ 104,000,000	\$
2. Prior Year-end		
(a) Debt	\$ 70,000,000	XXX
(b) Funding agreements		\$
(c) Other		XXX
(d) Aggregate total (a+b+c)	\$ 70,000,000	\$

(b) Maximum amount during reporting period (current year)

	Total
1. Debt	\$ 104,000,000
2. Funding agreements	
3. Other	
4. Aggregate total (Lines 1+2+3)	\$ 104,000,000

(c) FHLB - Prepayment obligations

	Does the Company Have Prepayment Obligations Under the Following Arrangements? (YES/NO)
1. Debt	NO
2. Funding agreements	NO
3. Other	NO

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

A. Defined Benefit Plan

The Plan terminated its defined benefit plan in 2015.

Supplemental Executive Retirement Plans (SERP)

The Supplemental Executive Retirement Plans (“SERP”) are non-qualified defined benefit pension plans for certain executives as designated by the Board of Directors. There are annuities and installment payments made to retired participants.

Effective January 1, 2014 the SERP was frozen for active executives as designated by the Board of Directors. The designated executives will no longer accrue additional benefits based on pay and service subsequent to December 31, 2013.

Postretirement Benefit Plans

Eligible employees hired prior to January 1, 1992, who retire on or after attaining normal retirement age and who have rendered specific years of service under the provisions of the Blue Cross & Blue Shield of Rhode Island Retirement Plan are entitled to certain postretirement health care, medical coverage, and life insurance benefits. The Plan may amend or change the postretirement benefits periodically. Effective January 1, 1993, except for those employees who have an exemption based on circumstances previously existing, these benefits are now subject to copayment provisions and other limitations. Effective April 1, 2013, a plan amendment for retiree insurance benefits was adopted whereby eligible active and former employees that had not attained retirement age of 55 or older and had not been collecting these benefits would not be entitled to these benefits upon retirement. The discontinued retiree benefits were life insurance and a group health insurance subsidy.

NOTES TO FINANCIAL STATEMENTS

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans (Continued)

(1) Change in benefit obligation

The following tables set forth the funding status and amounts recognized in the Plan's Statutory Statements of Admitted Assets, Liabilities and Reserves at December 31, 2024 and 2023 for the Defined Benefit Plan, for the SERP and the Postretirement Benefit Plan:

(a) Pension benefits

	Overfunded		Underfunded	
	2024	2023	2024	2023
1. Benefit obligation at beginning of year	\$	\$	\$ 3,281,291	\$ 3,163,478
2. Service cost				
3. Interest cost			153,493	154,359
4. Contribution by plan participants				
5. Actuarial gain / loss			(241,283)	66,101
6. Foreign currency exchange rate changes				
7. Benefits paid			(128,663)	(102,647)
8. Plan amendments				
9. Business combinations, divestitures, curtailments, settlements and special termination benefits				
10. Benefit obligation at end of year	\$	\$	\$ 3,064,838	\$ 3,281,291

(b) Postretirement benefits

	Overfunded		Underfunded	
	2024	2023	2024	2023
1. Benefit obligation at beginning of year	\$	\$	\$ 8,135,898	\$ 8,323,940
2. Service cost				
3. Interest cost			355,916	380,217
4. Contribution by plan participants				
5. Actuarial gain / loss			(615,392)	171,232
6. Foreign currency exchange rate changes				
7. Benefits paid			(746,866)	(739,491)
8. Plan amendments				
9. Business combinations, divestitures, curtailments, settlements and special termination benefits				
10. Benefit obligation at end of year	\$	\$	\$ 7,129,556	\$ 8,135,898

(2) Change in plan assets

	Pension Benefits		Postretirement Benefits		Special or Contractual Benefits Per SSAP No. 11	
	2024	2023	2024	2023	2024	2023
a. Fair value of plan assets at beginning of year	\$ -	\$ -	\$ -	\$ -	\$	\$
b. Actual return on plan assets						
c. Foreign currency exchange rate changes						
d. Reporting entity contribution	128,663	102,647	746,866	739,491		
e. Plan participants' contributions						
f. Benefits paid	(128,663)	(102,647)	(746,866)	(739,491)		
g. Business combinations, divestitures and settlements						
h. Fair value of plan assets at end of year	\$ -	\$ -	\$ -	\$ -	\$	\$

(3) Funded status

	Pension Benefits		Postretirement Benefits	
	2024	2023	2024	2023
a. Components				
1. Prepaid benefit costs	\$	\$	\$	\$
2. Overfunded plan assets				
3. Accrued benefit costs	3,170,315	3,145,485	8,475,252	9,078,552
4. Liability for pension benefits	105,477	135,806	(1,345,696)	(942,654)
b. Assets and liabilities recognized				
1. Assets (nonadmitted)	\$	\$	\$	\$
2. Liabilities recognized	3,064,838	3,281,291	7,129,556	8,135,898
c. Unrecognized liabilities	\$	\$	\$	\$

(4) Components of net periodic benefit cost

Net periodic benefit cost for 2024 and 2023 included the following components:

NOTES TO FINANCIAL STATEMENTS

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans (Continued)

	Pension Benefits		Postretirement Benefits		Special or Contractual Benefits Per SSAP No. 11	
	2024	2023	2024	2023	2024	2023
a. Service cost	\$	\$	\$	\$	\$	\$
b. Interest cost	153,493	154,359	355,916	380,217		
c. Expected return on plan assets						
d. Transition asset or obligation						
e. Gains and losses						
f. Prior service cost or credit			(212,350)	(212,350)		
g. Gain or loss recognized due to a settlement or curtailment						
h. Total net periodic benefit cost	\$ 153,493	\$ 154,359	\$ 143,566	\$ 167,867	\$	\$

- (5) Amounts in unassigned funds (surplus) recognized as components of net periodic benefit cost - Not Applicable
- (6) Amounts in unassigned funds (surplus) that have not yet been recognized as components of net periodic benefit cost - Not Applicable
- (7) Weighted-average assumptions used to determine net periodic benefit cost

Weighted-average assumptions used to determine net periodic benefit cost as of period-end:			2024	2023
a. Weighted-average discount rate			4.780 %	4.980 %
b. Expected long-term rate of return on plan assets			%	%
c. Rate of compensation increase			%	%
d. Interest crediting rates (for cash balance plans and other plans with promised interest crediting rates)			%	%
Weighted-average assumptions used to determine projected benefit obligations as of period-end:			2024	2023
e. Weighted-average discount rate			5.460 %	4.780 %
f. Rate of compensation increase			%	%
g. Interest crediting rates (for cash balance plans and other plans with promised interest crediting rates)			%	%

- (8) The accumulated benefit obligation for the SERP was \$3,064,838 and \$3,281,291 as of year ended 2024 and 2023 respectively
- (9) The assumed annual rate of increase in the per capita cost of medical benefits is 6.50% in 2024 and is assumed to decrease through years 2030 and remain level at 5.29% through 2040.
- (10) Estimated future payments, which reflect expected future service, as appropriate, are expected to be paid in the years indicated
- The following benefit payment, which is reflected expected future services, as appropriate, are expected to be paid.

Year	Amount
a. 2025	\$ 952,000
b. 2026	923,000
c. 2027	894,000
d. 2028	892,000
e. 2029	858,000
f. 2030 through 2034	3,822,000

- (11) The Plan expects to contribute \$155,000 to its SERP and \$797,000 to its postretirement benefits in 2025.
- (12) Amounts and types of securities of the reporting entity and related parties included in plan assets - Not Applicable
- (13) Alternative method used to amortize prior service amounts or net gains and losses - Not Applicable
- (14) Substantive commitments used as the basis for accounting for the benefit obligation - Not Applicable
- (15) Special or contractual termination benefits recognized during the period - Not Applicable
- (16) Significant changes in the benefit obligation or plan assets not otherwise disclosed - Not Applicable

NOTES TO FINANCIAL STATEMENTS

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans (Continued)

(17) Pension Plans with an accumulated benefit obligation in excess of plan asset:

	SERP		Postretirement	
	2024	2023	2024	2023
Projected benefit obligation	\$ 3,064,838	\$ 3,281,291	\$ 7,129,556	\$ 8,135,898
Accumulated benefit obligation	3,064,838	3,281,291	7,129,556	8,135,898
Fair value of plan assets	-	-	-	-

Pension Plans with plan asset in excess of accumulated benefit obligations:

	SERP		Postretirement	
	2024	2023	2024	2023
Projected benefit obligation	N/A	N/A	N/A	N/A
Accumulated benefit obligation	N/A	N/A	N/A	N/A
Fair value of plan assets	N/A	N/A	N/A	N/A

B. Investment Policies and Strategies of Plan Assets

Not applicable the Plan does not hold any plan assets.

C. Fair Value of Each Class of Plan Assets

- (1) Fair value measurements of plan assets at reporting date - Not Applicable
- (2) Valuation technique(s) and inputs to measure fair value - Not Applicable

D. Expected Long-Term Rate of Return for the Plan Assets

The Plan does not hold any plan assets.

E. Defined Contribution Plans

Participant contributions to the Plan are derived from voluntary salary reduction agreements with the Employer that is subject to the Internal Revenue Service (IRS) compensation deferral limits. Participants who are at least age 50 before the end of the Plan year may make catch-up contributions equal to any whole number percentage of their eligible compensation or whole dollar amount. Participants may not contribute in excess of the maximum allowed by the Internal Revenue Code (IRC). Employer contributions to the Plan are in an amount equal to 100% of a participant's contributions up to 6% of a participant's eligible compensation.

Upon enrollment in the plan, a participant may direct participant and employer contributions in 1% increments with a minimum contribution of 1% in any of the investment options. Participants may change their contribution percentage and investment selections in accordance with stated plan requirements. Participants that contribute on a pre-tax basis up to 6% an equal amount will be matched by the Plan. Total employer contributions to the 401(k) savings plan in 2024 and 2023 were approximately \$5,628,075 and \$5,356,823, respectively.

F. Multiemployer Plans - Not Applicable

G. Consolidated/Holding Company Plans - Not Applicable

H. Postemployment Benefits and Compensated Absences

The Plan provides for certain postemployment benefits including disability benefits for eligible employees. The Plan has not recorded a liability for these benefits at December 31, 2024 and 2023, respectively.

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17) - Not Applicable

13. Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations

- A. The Plan does not have any capital stock.
- B. The Plan does not have any preferred stock.
- C. The Plan does not have any dividend restrictions.
- D. The Plan does not have any ordinary dividends.
- E. The Plan does not have any paid dividends.
- F. The Plan does not have any restrictions on unassigned funds.
- G. The Plan does not have any advances to surplus unpaid.
- H. Stock Held for Special Purposes

The Plan does not have any conversion of preferred stock, employee stock options and stock purchase warrants.

I. Changes in Special Surplus Funds - Not Applicable

J. Unassigned Funds (Surplus)

The portion of unassigned funds (surplus) represented was reduced by each of the following item:

- a) Nonadmitted assets - \$75,673,978

K. Company-Issued Surplus Debentures or Similar Obligations

The Plan does not have any surplus notes.

NOTES TO FINANCIAL STATEMENTS

13. Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations (Continued)

L. Impact of Any Restatement Due to Prior Quasi-Reorganizations

The Plan did not have any quasi-reorganization in 2024.

M. The Plan did not have any quasi-reorganization in 2024.

14. Liabilities, Contingencies and Assessments

A. Contingent Commitments

The Plan is a defendant in several legal proceedings arising in the normal course of business. The Plan also remains a co-defendant in a multi-district litigation, consisting of two distinct assertions (one alleged by a class of subscribers, the other by a class of providers) in federal court relating to allegations that the Plan has acted in conspiracy with other Blue Cross and Blue Shield plans in violation of antitrust laws. The settlement on the subscriber side of the case has received final court approval and is in effect. As previously reported, multiple cases have been filed by plaintiffs who opted out of that subscriber settlement class, where the Plan is a co-defendant. Those cases remain ongoing. Additionally, a settlement has been reached with the provider plaintiffs, which has received preliminary court approval. That settlement process, including the class notice period, is ongoing, and has not received final court approval. While liability is presently difficult to estimate, it is management's belief that the final outcome on the provider side of the case, and with respect to any current opt-out cases, is not likely to have a material adverse effect on the Plan's financial position or results of operations, statutory reserves and risk-based capital. However, it is possible that a court decision or settlement, including the outcome of the provider settlement process, could have an unanticipated material adverse effect on the Plan's results of operations, and risk-based capital.

(1) Commitments or contingent commitment(s) to an SCA entity, joint venture, partnership, or limited liability company - Not Applicable

(2) Nature and circumstances of guarantee - Not Applicable

(3) Aggregate compilation of guarantee obligations - Not Applicable

B. Assessments

The Plan does not have any assessments.

(1) Not Applicable

(2) Assets (Liabilities) recognized from paid and accrued premium tax offsets and policy surcharges - Not Applicable

(3) Guaranty fund liabilities and assets related to long-term care insolvencies - Not Applicable

C. Gain Contingencies

The Plan does not have any gain contingencies.

D. Claims Related Extra Contractual Obligation and Bad Faith Losses Stemming from Lawsuits

The Plan did not have any claims related extra contractual obligation and bad faith losses stemming from lawsuits.

E. Joint and Several Liabilities

The Plan did not have any Joint and Several liability arrangements.

F. All Other Contingencies

All other contingencies see "A" above.

15. Leases

A. Lessee Operating Lease

(1) Leasing arrangements

The Plan leases office space and ground lease under operating leases. Rent expense for operating leases in 2024 and 2023 was approximately \$752,360 and \$620,959, respectively.

(2) For leases having initial or remaining noncancelable lease terms in excess of one year

(a) Minimum aggregate rental commitments at year end

The Plan is committed, under long-term noncancelable operating leases and installment purchase agreements to minimum payments as follows:

Year Ending December 31	Operating Leases
1. 2025.....	\$..... 877,620
2. 2026..... 880,523
3. 2027..... 805,154
4. 2028..... 748,693
5. 2029..... 503,960
6. Thereafter..... —
7. Total (sum of 1 through 6).....	<u>\$..... 3,815,950</u>

Certain rental commitments e.g. ground lease is a 97 year agreement through the year 2108 with two successive 75 year renewal options. Some of these renewals are subject to adjustments in future periods.

(b) Sublease minimum rentals to be received - Not Applicable

(3) The Plan is not involved in material sales – leaseback transactions.

NOTES TO FINANCIAL STATEMENTS

15. Leases (Continued)

B. Lessor Leases

(1) Operating leases

- (a) The Plan has several lease agreements for the use of its Corporate Office. The total rental square footage leased is 88,800 sq ft. The lease terms range from 88 months to 127 months with lease termination dates ranging from March 2025 through August 2029. Each arrangement is a triple net lease and lessees are responsible for electricity usage for the specific rented space.
- (b) Cost and carrying amount of leased property - Not Applicable
- (c) Future minimum lease payment receivables under non-cancelable leasing arrangements

	Year Ending December 31	Operating Leases
1. 2025	\$	3,004,809
2. 2026		2,530,030
3. 2027		1,500,025
4. 2028		1,499,566
5. 2029		891,940
6. Thereafter		—
7. Total (sum of 1 through 6)	\$	9,426,370

- (d) The Plan does not have contingent rentals.

(2) Leveraged leases

The Plan does not have leveraged leases.

16. Information About Financial Instruments With Off-Balance-Sheet Risk And Financial Instruments With Concentrations of Credit Risk

- 1. Face Amount of the Company's Financial Instruments with Off-Balance-Sheet Risk
The Plan does not have any swaps or option instruments.
- 2. The Plan does not have any interest rate swaps to reduce market risk.
- 3. The Plan does not have any credit related losses.
- 4. A pool of securities with a combined par value of \$43,040,000 are pledged to satisfy Blue Cross Blue Shield Association membership standards for out-of-area provider claim settlements.
The Plan also has pledged corporate and Treasury fixed income securities carrying a combined par value of \$182,022,017 to FHLB as collateral for its line of credit.

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

The Plan did not have a sale, transfer and servicing of financial assets and extinguishments of liabilities.

- A. Transfers of Receivables Reported as Sales - Not Applicable
- B. Transfer and Servicing of Financial Assets - Not Applicable
- C. Wash Sales - Not Applicable

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

A. ASO Plans

The Plan is not an ASO Administrator for uninsured A&H Plans and the uninsured portion of partially insured plans.

B. ASC Plans

The Plan is an ASC Administrator for uninsured A&H Plans and the uninsured portion of partially insured plans.

The gain from operations from Administrative Services Contract (ASC) uninsured plans and the uninsured portion of partially insured plans was as follows during December 31, 2024:

	ASC Uninsured Plans	Uninsured Portion of Partially Insured Plans	Total ASC
a. Gross reimbursement for medical cost incurred	\$ 1,341,120,242	\$ -	\$ 1,341,120,242
b. Gross administrative fees accrued	72,144,336	-	72,144,336
c. Total revenue	\$ 1,413,264,578	\$ -	\$ 1,413,264,578
d. Claims incurred	1,341,120,242	-	1,341,120,242
e. Variable cost	30,369,631	-	30,369,631
f. Contribution to fixed overhead	\$ 41,774,705	\$ -	\$ 41,774,705
g. Total fixed overhead	70,862,472	-	70,862,472
h. Total net gain or (loss) from operations	\$ (29,087,767)	\$ -	\$ (29,087,767)

C. Medicare or Other Similarly Structured Cost Based Reimbursement Contract

The Plan has a Medicare or similarly structured cost based reimbursement contract during 2024 and 2023.

The Medicare Part D program is a partially insured plan. The Plan recorded a receivable in amounts receivable relating to uninsured plans in the statutory basis of admitted assets, liabilities, and capital and surplus of \$56,570,000 as of December 31, 2024 for cost reimbursement under the Medicare Part D program for catastrophic reinsurance, low-income member cost-sharing subsidies and coverage gap discount programs.

NOTES TO FINANCIAL STATEMENTS

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

The Plan does not have direct premium written/produced by managing general agents/third party administrators.

20. Fair Value Measurements

A. Fair Value Measurement

(1) Fair value at reporting date

The Plan's financial assets and liabilities carried at fair value have been classified, for disclosure purposes, based on a hierarchy defined by FASB ASC 820, *Fair Value Measurements and Disclosures*. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level input that is significant to its measurement. For example, a Level 3 fair value measurement may include inputs that are both observable (Levels 1 and 2) and unobservable (Level 3). The levels of the fair value hierarchy are as follows:

- Level 1 - Values are unadjusted quoted prices for identical assets and liabilities in active markets accessible at the measurement date.
- Level 2 - Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices from those willing to trade in markets that are not active, or other inputs that are observable or can be corroborated by market data for the term of the instrument. Such inputs include market interest rates and volatilities, spreads, and yield curves.
- Level 3 - Certain inputs are unobservable (supported by little or no market activity) and significant to the fair value measurement. Unobservable inputs reflect the Plan's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date.

The following table provides information as of December 31, 2024 about the Plan's financial assets and liabilities measured at fair value on a recurring basis.

Description for each class of asset or liability	Level 1	Level 2	Level 3	Net Asset Value (NAV)	Total
a. Assets at fair value					
Bonds	\$ 434,061,347			\$ 434,061,347	\$ 434,061,347
Preferred stock-unaffiliated	19,046,132				19,046,132
Common stock-affiliated					
Common stock-unaffiliated	108,756,069	4,672,900	33,961,109		147,390,078
Total assets at fair value/NAV	\$ 127,802,201	\$ 438,734,247	\$ 33,961,109	\$ 600,497,557	\$ 600,497,557
b. Liabilities at fair value					
Line of Credit	\$ 104,220,360			\$ 104,220,360	\$ 104,220,360
Mortgage Loan		34,319,851			34,319,851
Total liabilities at fair value	\$ 138,540,211	\$ 138,540,211		\$ 138,540,211	\$ 138,540,211

The fair value of the Plan's equity securities categorized as Level 1 is based on quoted market prices for identical securities traded in active markets that are readily and regularly available to the Plan.

The fair value of the Plan's equity securities classified as Level 3 consist of private placement stocks for three companies for which there are limited or no observable valuation inputs. The fair value of these Level 3 equities is based upon analytics derived by the respective companies for which a fair value per share is published in the Securities Valuation Office manual.

(2) Fair value measurements in Level 3 of the fair value hierarchy

The following table presents the changes in our equity securities classified as Level 3 for the year-ended December 31, 2024.

Description	Beginning balance as of 01/01/2024	Transfers Into Level 3	Transfers Out of Level 3	Total Gains and (Losses) Included in Net Income	Total Gains and (Losses) Included in Surplus	Purchases	Issuances	Sales	Settlements	Ending Balance at 12/31/2024
a. Assets										
Common stock-affiliated	\$ 10,226,793				\$ (10,226,793)					\$ -
Common stock-unaffiliated	30,742,064				2,697,329	521,716				33,961,109
Total assets	\$ 40,968,857				\$ (7,529,464)	\$ 521,716				\$ 33,961,109
b. Liabilities										
Total liabilities										

There were unrealized losses of \$7,529,464 for the period ending December 31, 2024.

(3) There were no transfers between levels as of December 31, 2024.

(4) The Plan carries certain financial instruments carried at fair value. Other financial instruments are periodically measured at fair value, such as when impaired, or, for certain bonds and preferred stock when carried at the lower of cost or market.

(5) Derivatives - Not Applicable

B. Other Fair Value Disclosures - Not Applicable

C. Fair Values for All Financial Instruments by Level 1, 2 and 3

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	Level 1	Level 2	Level 3	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds	\$ 434,061,347	\$ 459,971,743	\$ 434,061,347	\$ 434,061,347		\$ 434,061,347	
Preferred stock-unaffiliated	19,046,132	19,046,132	19,046,132				
Common stock-affiliated							
Common stock-unaffiliated	147,390,078	14,739,078	108,756,069	4,672,900	33,961,109		

D. Not Practicable to Estimate Fair Value - Not Applicable

NOTES TO FINANCIAL STATEMENTS

20. Fair Value Measurements (Continued)

E. Nature and Risk of Investments Reported at NAV - Not Applicable

21. Other Items

A. Unusual or Infrequent Items

The Plan does not have any extraordinary items.

B. Troubled Debt Restructuring

The Plan does not have any troubled debt restructuring.

C. Other Disclosures

The Plan participates in the Federal Employee Health Benefits Program (FEHBP) with other Blue Cross Blue Shield Plans. This program includes a fully-insured experience-rated contract, commonly known as the Federal Employee Program (FEP), between the Office of Personnel Management (OPM) and BCBSA, which acts as an agent for the participating Blue Cross Blue Shield plans. Each participating plan, including the Plan, executes a contract with BCBSA which obligates these plans to underwrite FEP benefits in its service area.

Premium rates are developed by BCBSA and negotiated with OPM annually. These are the rates which each participating Blue Cross Blue Shield will receive to provide insurance to Federal employees that enrolled with Blue Cross Blue Shield FEP. The excess of gross premiums over the charges for the life of the program on an accrual basis is accounted for as a rate stabilization reserve (commonly referred to as the special reserve), as required by the contract between OPM and BCBSA.

Each year, OPM also allocates a portion of the premiums to a contingency reserve which may be utilized by participating plans in the event annual premiums paid to the insurance carrier are insufficient or the rate stabilization reserve falls below certain levels prescribed by OPM. Premiums paid to the carrier and available to each participating Blue Cross Blue Shield plan, including the special reserve and contingency reserve, including amounts unused from prior periods are held at the U.S. Treasury. Any premiums that remain in the rate stabilization reserve upon termination of the BCBSA contract, after the claims run-out and reimbursement of the allowable administrative expenses, would be returned to OPM for the benefit of the FEHBP. The FEP contract automatically renews each year unless written notice of termination is given by either party.

In accordance with the FEP contract, premium funds that exceed daily operating needs are held on behalf of the Plan in letter of credit accounts at the U.S. Treasury to provide funding for claims, administrative expenses, and other charges to the contract. The Plan, along with other Blue Cross Blue Shield plans who participate in the FEHBP contract, has an unrestricted right to draw funds held in the U.S. Treasury.

The Plan has recorded its allocable share of a special reserve fund held in the U.S. Treasury as an asset, with an equivalent amount recorded as a rate stabilization reserve. This amount is \$585,857 as of December 31, 2024 and is included in other current assets and other current liabilities in the accompanying consolidated balance sheets.

FEP represented approximately 3.7% of accounts receivable and approximately 7.4% of net revenue as of and for the year ended December 31, 2024, respectively.

Additionally, the Center for Medicare & Medicaid Services (CMS) adjusts payments to Medicare Advantage plans and Medicare Part D plans according to the predicted health status of each beneficiary as supported by data from health care providers. The Plan collects claim and encounter data from providers whom the Plan generally relies to appropriately code claim submissions and document applicable medical records. CMS then determines the risk score and payment amount for each enrolled member based on the health care data submitted and member demographic information.

CMS and the Office of Inspector General for Health and Human Services periodically perform RADV audits of selected Medicare health plans to validate the coding practices of and supporting documentation maintained by health care providers. Such audits have in the past resulted in, and in the future could result in, retrospective adjustments to payments made to the Plan, fines, corrective action plans or other adverse action by CMS.

D. Business Interruption Insurance Recoveries

The Plan did not have any business interruption insurance recoveries in 2024.

E. State Transferable and Non-Transferable Tax Credits

(1) Carrying value of transferable and non-transferable state tax credits gross of any related tax liabilities and total unused transferable and non-transferable state tax credits by state and in total

Description of State Transferable and Non-transferable Tax Credits	State	Carrying Value	Unused Amount
Historic Investment Tax Credit.....	RI.....	\$..... 5,948,250	\$..... 6,487,500
Total.....		<u>\$..... 5,948,250</u>	<u>\$..... 6,487,500</u>

(2) Method of estimating utilization of remaining transferable and non-transferable state tax credits

The Plan estimated the utilization of the remaining non-transferable state tax credits by projecting future premium taking into account policy growth and rate changes, projecting future tax liability based on projected premium, tax rates and tax credits, and comparing projected future tax liability to the availability of remaining non-transferable state tax credits.

(3) Impairment loss

The Plan did not have any impairment losses for state transferable tax credits in 2024.

(4) State tax credits admitted and nonadmitted

	Total Admitted	Total Nonadmitted
a. Transferable.....	\$..... 5,948,250	\$.....
b. Non-transferable.....	\$.....	\$.....

F. Subprime-Mortgage-Related Risk Exposure

(1) The following is the Plan's narrative description of a subprime investment. A mortgage loan which has one or more of the following attributes: weak credit score high debt-to-income-ratio, high loan-to-value ratio or undocumented income.

(2) Direct exposure through investments in subprime mortgage loans - Not Applicable

NOTES TO FINANCIAL STATEMENTS

21. Other Items (Continued)

- (3) Direct exposure through other investments - Not Applicable
- (4) Underwriting exposure to subprime mortgage risk through Mortgage Guaranty or Financial Guaranty insurance coverage - Not Applicable
- G. Retained Assets - Not Applicable
- H. Insurance-Linked Securities (ILS) Contracts
- The Plan did not receive proceeds from insurance-linked securities.
- I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy
- The Plan has not realized on life insurance policy.

22. Events Subsequent

Nonrecognized Subsequent Event:

There are no recognized or non-recognized events subsequent to December 31, 2024, that require recognition or disclosure.

23. Reinsurance

A. Ceded Reinsurance Report

Section 1 – General Interrogatories

- (1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the company or by any representative, officer, trustee, or director of the company?
- Yes () No (X)
- (2) Have any policies issued by the company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor or any other person not primarily engaged in the insurance business?
- Yes () No (X)

Section 2 – Ceded Reinsurance Report – Part A

- (1) Does the company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credits?
- Yes () No (X)
- (2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?
- Yes () No (X)

Section 3 – Ceded Reinsurance Report – Part B

- (1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the company may consider the current or anticipated experience of the business reinsured in making this estimate. \$ —
- (2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the company as of the effective date of the agreement?
- Yes () No (X)

B. Uncollectible Reinsurance

The Plan did not experience a write-off for uncollectible reinsurance.

C. Commutation of Reinsurance Reflected in Income and Expenses

The Plan did not experience a commutation of ceded reinsurance.

D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation - Not Applicable

E. Reinsurance Credit - Not Applicable

24. Retrospectively Rated Contracts & Contracts Subject to Redetermination

A. Method Used to Estimate

The Plan estimates accrued retrospective premium adjustments for its group health insurance business based on the Plan's underwriting polices, experience rating practices and claims reserve calculation.

B. Method Used to Record

The Plan records accrued retrospective premium as an adjustment to earned premium.

C. Amount and Percent of Net Retrospective Premiums

The amount of net premiums written by the Plan at December 31, 2024 that are subject to retrospective rating features was \$6,331,456, that represented 0.29% of the total net premiums written. No other net premiums written by the Plan are subject to retrospective rating features.

NOTES TO FINANCIAL STATEMENTS

24. Retrospectively Rated Contracts & Contracts Subject to Redetermination (Continued)

D. Medical Loss Ratio Rebates Required Pursuant to the Public Health Service Act

The Plan did not have Medical Loss Ratio rebates at December 31, 2024.

	(1)	(2)	(3)	(4)	(5)
	Individual	Small Group Employer	Large Group Employer	Other Categories with Rebates	Total
Prior Reporting Year					
(1) Medical loss ratio rebates incurred	\$	\$	\$	\$	\$
(2) Medical loss ratio rebates paid					
(3) Medical loss ratio rebates unpaid					
(4) Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	
(5) Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	
(6) Rebates unpaid net of reinsurance	XXX	XXX	XXX	XXX	\$
Current Reporting Year-to-Date					
(7) Medical loss ratio rebates incurred	\$	\$	\$	\$	\$
(8) Medical loss ratio rebates paid					
(9) Medical loss ratio rebates unpaid					
(10) Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	
(11) Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	
(12) Rebates unpaid net of reinsurance	XXX	XXX	XXX	XXX	\$

E. Risk-Sharing Provisions of the Affordable Care Act (ACA)

Effective January 1, 2014, the ACA imposed fees and premium stabilization provisions on health insurance issuers offering commercial health insurance. The three premium stabilization programs are commonly referred to as the 3R's – risk adjustment, risk corridor and reinsurance.

- Risk Adjustment - This permanent program is designed to mitigate the potential impact of adverse selection and provide stability for health insurance issuers and applies to all non-grandfathered plans in the individual and small group markets both on and off the insurance exchanges. Premium adjustments pursuant to the risk adjustment program are accounted for as premium subject to redetermination and user fees are accounted for as assessments.
- Risk Corridor - This temporary program was designed to provide aggregate protection for variability for issuers in the individual and small group markets during the 2014 to 2016 time period and applies to qualified health plans (QHPs) in the individual and small group markets both on and off the insurance exchanges. Premium adjustments pursuant to the risk corridor program are accounted for as premium adjustments for retrospectively rated contracts.

The plan has accident and health insurance premiums for CY 2024 subject to the risk sharing provisions of ACA.

(1) Accident and health insurance premium subject to the Affordable Care Act risk-sharing provisions

Did the reporting entity write accident and health insurance premium which is subject to the Affordable Care Act risk sharing provisions?
YES

(2) Impact of Risk-Sharing Provisions of the Affordable Care Act on admitted assets, liabilities and revenue for the current year

	Amount
a. Permanent ACA Risk Adjustment Program	
Assets	
1. Premium adjustments receivable due to the ACA risk adjustment (including high-risk pool payments)	\$ 13,140,000
Liabilities	
2. Risk adjustment user fees payable for ACA risk adjustment	\$ 145,148
3. Premium adjustments payable due to ACA risk adjustment (including high-risk pool premium)	
Operations (Revenue & Expense)	
4. Reported as revenue in premium for accident and health contracts (written/collected) due to ACA risk adjustment	\$ 12,902,717
5. Reported in expenses as ACA risk adjustment user fees (incurred/paid)	149,621

NOTES TO FINANCIAL STATEMENTS

24. Retrospectively Rated Contracts & Contracts Subject to Redetermination (Continued)

(3) Roll-forward of prior year ACA risk-sharing provisions for the following asset (gross of any nonadmission) and liability balances, along with the reasons for adjustments to prior year balance

				Differences		Adjustments		Unsettled Balances as of the Reporting Date	
Accrued During the Prior Year on Business Written Before Dec 31 of the Prior Year		Received or Paid as of the Current Year on Business Written Before Dec 31 of the Prior Year		Prior Year Accrued Less Payments (Col 1 - 3)	Prior Year Accrued Less Payments (Col 2 - 4)	To Prior Year Balances	To Prior Year Balances	Cumulative Balance from Prior Years (Col 1-3+7)	Cumulative Balance from Prior Years (Col 2-4+8)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Ref	Receivable (Payable)
a. Permanent ACA Risk Adjustment Program									
1. Premium adjustments receivable (including high risk pool payments)									
\$ 11,930,000		\$ 11,692,716		\$ 237,284		\$ (237,284)		A	\$ - \$
2. Premium adjustments (payable) (including high risk pool premium)									
	(148,845)		(153,318)		4,473		(4,473)	B	-
3. Subtotal ACA Permanent Risk Adjustment Program									
\$ 11,930,000	\$ (148,845)	\$ 11,692,716	\$ (153,318)	\$ 237,284	\$ 4,473	\$ (237,284)	\$ (4,473)		\$ - \$

Explanations of Adjustments
A: Risk Adjustment updated based on HHS Notification
B: Risk Adjustment updated based on HHS Notification

25. Change in Incurred Claims and Claim Adjustment Expenses

A. Reasons for Changes in the Provision for Incurred Claim and Claim Adjustment Expenses Attributable to Insured Events of Prior Years

Reserves as of December 31, 2023, were \$197,265,000 and as of December 31, 2024, \$100,834,000 has been paid for incurred claims and claim adjustment expenses attributable to insured events of prior years. Reserves remaining for prior years are now \$27,239,000 as a result of re-estimation of unpaid claims and claim adjustment expenses principally on Comprehensive and Medicare lines of insurance. Therefore, there has been a \$69,192,000 favorable prior-year development since December 31, 2023, to December 31, 2024. The decrease is generally the result of ongoing analysis of recent loss development trends. Original estimates are increased or decreased, as additional information becomes known regarding individual claims. The Plan did not experience prior year claim development on retrospectively rated policies.

B. Significant Changes in Methodologies and Assumptions Used in Calculating the Liability for Unpaid Claims and Claim Adjustment Expenses - Not Applicable

26. Intercompany Pooling Arrangements

The Plan is not part of any intercompany pooling arrangement.

27. Structured Settlements - Not Applicable

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

Quarter	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received Within 90 Days of Billing	Actual Rebates Received Within 91 to 180 Days of Billing	Actual Rebates Received More Than 180 Days After Billing
12/31/2024	\$ 53,236,238	\$	\$	\$	\$
09/30/2024	53,816,756	53,306,893	52,944,692		
06/30/2024	47,700,140	48,417,637	48,661,277		19,320
03/31/2024	47,331,608	46,136,271	41,850,108		3,592,060
12/31/2023	48,909,138	46,237,572	42,539,000		4,097,251
09/30/2023	44,788,958	47,026,983	43,517,650		3,509,333
06/30/2023	41,172,120	45,105,158	41,537,969		3,567,189
03/31/2023	38,084,117	39,274,459	37,068,877		2,205,583
12/31/2022	37,110,096	35,959,555	34,073,475		1,886,080
09/30/2022	36,568,718	36,267,774	33,759,645		2,508,128
06/30/2022	32,874,159	35,509,453	32,751,382		2,758,071
03/31/2022	31,636,681	33,206,811	29,654,008		3,552,803

B. Risk-Sharing Receivables - Not Applicable

29. Participating Policies

Participating policies do not apply to the Plan.

30. Premium Deficiency Reserves

The Plan has a statutory premium deficiency reserve (PDR) of \$52,860,000 and \$39,400,000 for the periods ended December 31, 2024 and December 31, 2023, respectively. The PDR related to the Commercial, Medicare Supplement and Medicare Advantage lines of business for the period ended December 31, 2024 and December 31, 2023.

1. Liability carried for premium deficiency reserves:	\$52,860,000
2. Date of the most recent evaluation of this liability:	12/31/2024
3. Was anticipated investment income utilized in the calculation?	YES

NOTES TO FINANCIAL STATEMENTS

31. Anticipated Salvage and Subrogation

The amount of undiscounted estimated salvage and subrogation recoverable, taken into account in determining the undiscounted unpaid losses as reported in the Underwriting and Investment Exhibit and Page 3 – Liabilities, Reserves and Special Funds, Line I for December 31, 2024 and 2023, was \$14,967,000 and \$17,135,000, respectively.

GENERAL INTERROGATORIES

PART 1 – COMMON INTERROGATORIES

GENERAL

1.1 Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of which is an insurer?

Yes ☒ No ☐

If yes, complete Schedule Y, Parts 1, 1A, 2 and 3

1.2 If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent or with such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statement providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (NAIC) in its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting entity subject to standards and disclosure requirements substantially similar to those required by such Act and regulations?

Yes ☒ No ☐ N/A ☐

1.3 State Regulating?

RHODE ISLAND

1.4 Is the reporting entity publicly traded or a member of a publicly traded group?

Yes ☐ No ☒

1.5 If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group.

2.1 Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity?

Yes ☐ No ☒

2.2 If yes, date of change:

3.1 State as of what date the latest financial examination of the reporting entity was made or is being made.

12/31/2023

3.2 State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released.

12/31/2023

3.3 State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date).

01/30/2025

3.4 By what department or departments?

RHODE ISLAND DEPARTMENT OF BUSINESS REGULATION - INSURANCE DIVISION

3.5 Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement filed with departments?

Yes ☒ No ☐ N/A ☐

3.6 Have all of the recommendations within the latest financial examination report been complied with?

Yes ☒ No ☐ N/A ☐

4.1 During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity) receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:

4.11 sales of new business?

Yes ☐ No ☒

4.12 renewals?

Yes ☐ No ☒

4.2 During the period covered by this statement, did any sales/service organization owned in whole or in part by the reporting entity or an affiliate, receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:

4.21 sales of new business?

Yes ☐ No ☒

4.22 renewals?

Yes ☐ No ☒

5.1 Has the reporting entity been a party to a merger or consolidation during the period covered by this statement?

Yes ☐ No ☒

If yes, complete and file the merger history data file with the NAIC.

GENERAL INTERROGATORIES

5.2 If yes, provide the name of the entity, NAIC Company Code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.

1 Name of Entity	2 NAIC Company Code	3 State of Domicile

6.1 Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended or revoked by any governmental entity during the reporting period? Yes [] No [X]

6.2 If yes, give full information:
.
.
.
.

7.1 Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity? Yes [] No [X]

7.2 If yes,
7.21 State the percentage of foreign control. _____ %
7.22 State the nationality(s) of the foreign person(s) or entity(s); or if the entity is a mutual or reciprocal, the nationality of its manager or attorney-in-fact and identify the type of entity(s) (e.g., individual, corporation, government, manager or attorney-in-fact).

1 Nationality	2 Type of Entity

8.1 Is the company a subsidiary of a depository institution holding company (DIHC) or a DIHC itself, regulated by the Federal Reserve Board? Yes [] No [X]

8.2 If response to 8.1 is yes, please identify the name of the DIHC.
.
.
.
.

8.3 Is the company affiliated with one or more banks, thrifts or securities firms? Yes [] No [X]

8.4 If response to 8.3 is yes, please provide the names and locations (city and state of the main office) of any affiliates regulated by a federal financial regulatory services agency [i.e. the Federal Reserve Board (FRB), the Office of the Comptroller of the Currency (OCC), the Federal Deposit Insurance Corporation (FDIC) and the Securities Exchange Commission (SEC)] and identify the affiliate's primary federal regulator.

1 Affiliate Name	2 Location (City, State)	3 FRB	4 OCC	5 FDIC	6 SEC

8.5 Is the reporting entity a depository institution holding company with significant insurance operations as defined by the Board of Governors of Federal Reserve System or a subsidiary of the depository institution holding company? Yes [] No [X]

8.6 If response to 8.5 is no, is the reporting entity a company or subsidiary of a company that has otherwise been made subject to the Federal Reserve Board's capital rule? Yes [] No [X] N/A []

9. What is the name and address of the independent certified public accountant or accounting firm retained to conduct the annual audit?
Deloitte & Touche LLP, 185 Asylum Street, City Place I, 33rd Floor, Hartford, CT 06103
.
.
.

GENERAL INTERROGATORIES

10.1 Has the insurer been granted any exemptions to the prohibited non-audit services provided by the certified independent public accountant requirements as allowed in Section 7H of the Annual Financial Reporting Model Regulation (Model Audit Rule), or substantially similar state law or regulation?

Yes ☐ No ☒

10.2 If response to 10.1 is yes, provide information related to this exemption:

10.3 Has the insurer been granted any exemptions related to the other requirements of the Annual Financial Reporting Model Regulation as allowed for in Section 18A of the Model Regulation, or substantially similar state law or regulation?

Yes ☐ No ☒

10.4 If response to 10.3 is yes, provide information related to this exemption:

10.5 Has the reporting entity established an Audit Committee in compliance with the domiciliary state insurance laws?

Yes ☒ No ☐ N/A ☐

10.6 If the response to 10.5 is no or n/a, please explain.

11. What is the name, address and affiliation (officer/employee of the reporting entity or actuary/consultant associated with an actuarial consulting firm) of the individual providing the statement of actuarial opinion/certification?
BRIAN MACKINTOSH IS THE CHIEF ACTUARY OF BLUE CROSS BLUE SHIELD OF RHODE ISLAND. THE ADDRESS IS 500 EXCHANGE STREET, PROVIDENCE RI, 02903.

12.1 Does the reporting entity own any securities of a real estate holding company or otherwise hold real estate indirectly?

Yes ☐ No ☒

12.11 Name of real estate holding company

12.12 Number of parcels involved

12.13 Total book/adjusted carrying value

\$

12.2 If yes, provide explanation:

13. FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITIES ONLY:

13.1 What changes have been made during the year in the United States manager or the United States trustees of the reporting entity?

13.2 Does this statement contain all business transacted for the reporting entity through its United States Branch on risks wherever located?

Yes ☐ No ☒

13.3 Have there been any changes made to any of the trust indentures during the year?

Yes ☐ No ☒

13.4 If answer to (13.3) is yes, has the domiciliary or entry state approved the changes?

Yes ☐ No ☒ N/A ☐

GENERAL INTERROGATORIES

14.1 Are the senior officers (principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions) of the reporting entity subject to a code of ethics, which includes the following standards?

a. Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;

b. Full, fair, accurate, timely and understandable disclosure in the periodic reports required to be filed by the reporting entity;

c. Compliance with applicable governmental laws, rules, and regulations;

d. The prompt internal reporting of violations to an appropriate person or persons identified in the code; and

e. Accountability for adherence to the code.

Yes ☒ No ☐

14.11 If the response to 14.1 is no, please explain:

14.2 Has the code of ethics for senior managers been amended? Yes ☐ No ☒

14.21 If the response to 14.2 is yes, provide information related to amendment(s).

14.3 Have any provisions of the code of ethics been waived for any of the specified officers? Yes ☐ No ☒

14.31 If the response to 14.3 is yes, provide the nature of any waiver(s).

15.1 Is the reporting entity the beneficiary of a Letter of Credit that is unrelated to reinsurance where the issuing or confirming bank is not on the SVO Bank List? Yes ☐ No ☒

15.2 If the response to 15.1 is yes, indicate the American Bankers Association (ABA) Routing Number and the name of the issuing or confirming bank of the Letter of Credit and describe the circumstances in which the Letter of Credit is triggered.

1 American Bankers Association (ABA) Routing Number	2 Issuing or Confirming Bank Name	3 Circumstances That Can Trigger the Letter of Credit	4 Amount

BOARD OF DIRECTORS

16. Is the purchase or sale of all investments of the reporting entity passed upon either by the board of directors or a subordinate committee thereof? Yes ☒ No ☐

17. Does the reporting entity keep a complete permanent record of the proceedings of its board of directors and all subordinate committees thereof? Yes ☒ No ☐

18. Has the reporting entity an established procedure for disclosure to its board of directors or trustees of any material interest or affiliation on the part of any of its officers, directors, trustees or responsible employees that is in conflict or is likely to conflict with the official duties of such person? Yes ☒ No ☐

FINANCIAL

19. Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Generally Accepted Accounting Principles)? Yes ☐ No ☒

27.3

GENERAL INTERROGATORIES

25.06 Does your securities lending program require 102% (domestic securities) and 105% (foreign securities) from the counterparty at the outset of the contract? Yes [] No [] N/A [X]

25.07 Does the reporting entity non-admit when the collateral received from the counterparty falls below 100%? Yes [] No [] N/A [X]

25.08 Does the reporting entity or the reporting entity's securities lending agent utilize the Master Securities Lending Agreement (MSLA) to conduct securities lending? Yes [] No [] N/A [X]

25.09 For the reporting entity's security lending program, state the amount of the following as of December 31 of the current year:

25.091 Total fair value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2 \$

25.092 Total book adjusted/carrying value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2 \$

25.093 Total payable for securities lending reported on the liability page \$

26.1 Were any of the stocks, bonds or other assets of the reporting entity owned at December 31 of the current year not exclusively under the control of the reporting entity or has the reporting entity sold or transferred any assets subject to a put option contract that is currently in force? (Exclude securities subject to Interrogatory 21.1 and 25.03). Yes [X] No []

26.2 If yes, state the amount thereof at December 31 of the current year:

26.21	Subject to repurchase agreements	\$ 84,398
26.22	Subject to reverse repurchase agreements	\$
26.23	Subject to dollar repurchase agreements	\$
26.24	Subject to reverse dollar repurchase agreements	\$
26.25	Placed under option agreements	\$
26.26	Letter stock or securities restricted as to sale - excluding FHLB Capital Stock	\$
26.27	FHLB Capital Stock	\$ 4,672,900
26.28	On deposit with states	\$
26.29	On deposit with other regulatory bodies	\$
26.30	Pledged as collateral - excluding collateral pledged to an FHLB	\$ 43,040,000
26.31	Pledged as collateral to FHLB - including assets backing funding agreements	\$ 181,783,000
26.32	Other	\$

26.3 For category (26.26) provide the following:

1 Nature of Restriction	2 Description	3 Amount

27.1 Does the reporting entity have any hedging transactions reported on Schedule DB? Yes [] No [X]

GENERAL INTERROGATORIES

27.2 If yes, has a comprehensive description of the hedging program been made available to the domiciliary state?

Yes ☐ No ☐ N/A ☒

If no, attach a description with this statement.

LINES 27.3 through 27.5 : FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY:

27.3 Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity?

Yes ☐ No ☒

27.4 If the response to 27.3 is YES, does the reporting entity utilize:

27.41Special accounting provision of SSAP No. 108

27.42Permitted accounting practice

27.43Other accounting guidance

Yes ☐ No ☒

Yes ☐ No ☒

Yes ☐ No ☒

27.5 By responding YES to 27.41 regarding utilizing the special accounting provisions of SSAP No. 108, the reporting entity attests to the following:

Yes ☐ No ☒

- The reporting entity has obtained explicit approval from the domiciliary state.
- Hedging strategy subject to the special accounting provisions is consistent with the requirements of VM-21.
- Actuarial certification has been obtained which indicates that the hedging strategy is incorporated within the establishment of VM-21 reserves and provides the impact of the hedging strategy within the Actuarial Guideline Conditional Tail Expectation Amount.
- Financial Officer Certification has been obtained which indicates that the hedging strategy meets the definition of a Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy is the hedging strategy being used by the company in its actual day-to-day risk mitigation efforts.

28.1 Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible into equity, or, at the option of the issuer, convertible into equity?

Yes ☐ No ☒

28.2 If yes, state the amount thereof at December 31 of the current year.

\$

29. Excluding items in Schedule E - Part 3 - Special Deposits, real estate, mortgage loans and investments held physically in the reporting entity's offices, vaults or safety deposit boxes, were all stocks, bonds and other securities, owned throughout the current year held pursuant to a custodial agreement with a qualified bank or trust company in accordance with Section 1, III - General Examination Considerations, F. Outsourcing of Critical Functions, Custodial or Safekeeping Agreements of the NAIC Financial Condition Examiners Handbook?

Yes ☒ No ☐

29.01 For agreements that comply with the requirements of the NAIC Financial Condition Examiners Handbook, complete the following:

1 Name of Custodian(s)	2 Custodian's Address
NORTHERN TRUST	333 S. WABASH AVE., WB-42 CHICAGO, IL 60604
RELIANCE TRUST COMPANY	601 RIVERSIDE AVENUE, JACKSONVILLE, FL 32204

29.02 For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location and a complete explanation:

1 Name(s)	2 Location(s)	3 Complete Explanation(s)

29.03 Have there been any changes, including name changes, in the custodian(s) identified in 29.01 during the current year?

Yes ☐ No ☒

29.04 If yes, give full and complete information relating thereto:

1 Old Custodian	2 New Custodian	3 Date of Change	4 Reason

27.6

GENERAL INTERROGATORIES

29.05 Investment management - Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. This includes both primary and sub-advisors. For assets that are managed internally by employees of the reporting entity, note as such. ["... that have access to the investment accounts"; "...handle securities"]

1 Name Firm or Individual	2 Affiliation
BlackRock Financial Management, Inc.	U

29.0597 For those firms/individuals listed in the table for Question 29.05, do any firms/individuals unaffiliated with the reporting entity (i.e., designated with a "U") manage more than 10% of the reporting entity's invested assets? Yes [X] No []

29.0598 For firms/individuals unaffiliated with the reporting entity (i.e., designated with a "U") listed in the table for Question 29.05, does the total assets under management aggregate to more than 50% of the reporting entity's invested assets? Yes [X] No []

29.06 For those firms or individuals listed in the table 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1 Central Registration Depository Number	2 Name Firm or Individual	3 Legal Entity Identifier (LEI)	4 Registered With	5 Investment Managem Agreement (IMA) Filed
107105	BlackRock Financial Management, Inc.	549300LVXYIVJKE13M84	SECURITIES EXCHANGE COM	No

30.1 Does the reporting entity have any diversified mutual funds reported in Schedule D – Part 2 (diversified according to the Securities and Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5 (b) (1)])? Yes [X] No []

30.2 If yes, complete the following schedule:

1 CUSIP #	2 Name of Mutual Fund	3 Book/Adjusted Carrying Value
024071-81-3	AMERICAN FUNDS BAL R6	37,375
649280-81-5	AMERICAN FUNDS NWLD R6	34,736
256219-10-6	DODGE & COX STCK I	53,340
315911-75-0	FIDELITY 500 INDEX	1,023,986
315911-72-7	FIDELITY INTERNATIONAL IX	6,174
316146-35-6	FIDELITY US BOND INDEX	272,145
41665H-78-9	HARTFD:SCHR EM E SDR	10,881,680
57630E-87-5	MASSMUTUAL S:BL CH I	2,343
57630G-45-8	MASSMUTUAL S:TRP 25 I	419,510
57630G-41-7	MASSMUTUAL S:TRP 30 I	20,622
57630G-32-6	MASSMUTUAL S:TRP 40 I	18,567
57630G-27-6	MASSMUTUAL S:TRP 45 I	308,327
57630G-14-4	MASSMUTUAL S:TRP 60 I	27,639
57630G-18-5	MASSMUTUAL SELECT TRP RETIREMENT 2055 I	20,628
57629H-35-0	MASSMUTUAL:CR B I	113,311
552966-80-6	MFS INTERNATIONAL EQT R6	22,087,999
704329-24-2	PAYDEN:EM MKT BD SI	11,673,580
779562-20-6	T ROWE PRICE NH I	118,645
922908-83-5	VANGUARD MD-CP I INST	289,258
921908-87-7	VANGUARD RE IDX ADM	165,063
922908-87-6	VANGUARD S-C ID INST	285,988
969251-71-9	WM BLAIR:INTL LDRS I	169,948
30.2999 TOTAL		48,030,864

GENERAL INTERROGATORIES

30.3 For each mutual fund listed in the table above, complete the following schedule:

1	2	3	4
Name of Mutual Fund (from above table)	Name of Significant Holding of the Mutual Fund	Amount of Mutual Fund's Book/Adjusted Carrying Value Attributable to the Holding	Date of Valuation
024071-81-3	AMERICAN FUNDS BAL R6	37,375	12/31/2024
024071-81-3	AMERICAN FUNDS BAL R6	37,375	12/31/2024
024071-81-3	AMERICAN FUNDS BAL R6	37,375	12/31/2024
024071-81-3	AMERICAN FUNDS BAL R6	37,375	12/31/2024
649280-81-5	AMERICAN FUNDS NWLD R6	37,375	12/31/2024
649280-81-5	AMERICAN FUNDS NWLD R6	34,736	12/31/2024
649280-81-5	AMERICAN FUNDS NWLD R6	34,736	12/31/2024
649280-81-5	AMERICAN FUNDS NWLD R6	34,736	12/31/2024
649280-81-5	AMERICAN FUNDS NWLD R6	34,736	12/31/2024
649280-81-5	AMERICAN FUNDS NWLD R6	34,736	12/31/2024
256219-10-6	DODGE & COX STCK I	53,340	12/31/2024
256219-10-6	DODGE & COX STCK I	53,340	12/31/2024
256219-10-6	DODGE & COX STCK I	53,340	12/31/2024
256219-10-6	DODGE & COX STCK I	53,340	12/31/2024
256219-10-6	DODGE & COX STCK I	53,340	12/31/2024
315911-75-0	FIDELITY 500 INDEX	1,023,986	12/31/2024
315911-75-0	FIDELITY 500 INDEX	1,023,986	12/31/2024
315911-75-0	FIDELITY 500 INDEX	1,023,986	12/31/2024
315911-75-0	FIDELITY 500 INDEX	1,023,986	12/31/2024
315911-75-0	FIDELITY 500 INDEX	1,023,986	12/31/2024
315911-72-7	FIDELITY INTERNATIONAL IX	6,174	12/31/2024
315911-72-7	FIDELITY INTERNATIONAL IX	6,174	12/31/2024
315911-72-7	FIDELITY INTERNATIONAL IX	6,174	12/31/2024
315911-72-7	FIDELITY INTERNATIONAL IX	6,174	12/31/2024
315911-72-7	FIDELITY INTERNATIONAL IX	6,174	12/31/2024
316146-35-6	FIDELITY US BOND INDEX	272,145	12/31/2024
316146-35-6	FIDELITY US BOND INDEX	272,145	12/31/2024
316146-35-6	FIDELITY US BOND INDEX	272,145	12/31/2024
316146-35-6	FIDELITY US BOND INDEX	272,145	12/31/2024
316146-35-6	FIDELITY US BOND INDEX	272,145	12/31/2024
41665H-78-9	HARTFD:SCHR EM E SDR	10,881,680	12/31/2024
41665H-78-9	HARTFD:SCHR EM E SDR	10,881,680	12/31/2024
41665H-78-9	HARTFD:SCHR EM E SDR	10,881,680	12/31/2024
41665H-78-9	HARTFD:SCHR EM E SDR	10,881,680	12/31/2024
41665H-78-9	HARTFD:SCHR EM E SDR	10,881,680	12/31/2024
57630E-87-5	MASSMUTUAL S:BL CH I	2,343	12/31/2024
57630E-87-5	MASSMUTUAL S:BL CH I	2,343	12/31/2024
57630E-87-5	MASSMUTUAL S:BL CH I	2,343	12/31/2024
57630E-87-5	MASSMUTUAL S:BL CH I	2,343	12/31/2024
57630E-87-5	MASSMUTUAL S:BL CH I	2,343	12/31/2024
57630G-45-8	MASSMUTUAL S:TRP 25 I	419,510	12/31/2024
57630G-45-8	MASSMUTUAL S:TRP 25 I	419,510	12/31/2024
57630G-45-8	MASSMUTUAL S:TRP 25 I	419,510	12/31/2024
57630G-45-8	MASSMUTUAL S:TRP 25 I	419,510	12/31/2024
57630G-45-8	MASSMUTUAL S:TRP 25 I	419,510	12/31/2024
57630G-41-7	MASSMUTUAL S:TRP 30 I	20,622	12/31/2024
57630G-41-7	MASSMUTUAL S:TRP 30 I	20,622	12/31/2024
57630G-41-7	MASSMUTUAL S:TRP 30 I	20,622	12/31/2024
57630G-41-7	MASSMUTUAL S:TRP 30 I	20,622	12/31/2024
57630G-41-7	MASSMUTUAL S:TRP 30 I	20,622	12/31/2024
57630G-32-6	MASSMUTUAL S:TRP 40 I	18,567	12/31/2024
57630G-32-6	MASSMUTUAL S:TRP 40 I	18,567	12/31/2024
57630G-32-6	MASSMUTUAL S:TRP 40 I	18,567	12/31/2024
57630G-32-6	MASSMUTUAL S:TRP 40 I	18,567	12/31/2024
57630G-32-6	MASSMUTUAL S:TRP 40 I	18,567	12/31/2024
57630G-27-6	MASSMUTUAL S:TRP 45 I	308,327	12/31/2024
57630G-27-6	MASSMUTUAL S:TRP 45 I	308,327	12/31/2024
57630G-27-6	MASSMUTUAL S:TRP 45 I	308,327	12/31/2024
57630G-27-6	MASSMUTUAL S:TRP 45 I	308,327	12/31/2024
57630G-27-6	MASSMUTUAL S:TRP 45 I	308,327	12/31/2024
57630G-14-4	MASSMUTUAL S:TRP 60 I	27,639	12/31/2024
57630G-14-4	MASSMUTUAL S:TRP 60 I	27,639	12/31/2024

GENERAL INTERROGATORIES

1	2	3	4
Name of Mutual Fund (from above table)	Name of Significant Holding of the Mutual Fund	Amount of Mutual Fund's Book/Adjusted Carrying Value Attributable to the Holding	Date of Valuation
57630G-14-4	MASSMUTUAL S:TRP 60 I	27,639	12/31/2024
57630G-14-4	MASSMUTUAL S:TRP 60 I	27,639	12/31/2024
57630G-14-4	MASSMUTUAL S:TRP 60 I	27,639	12/31/2024
57630G-18-5	MASSMUTUAL SELECT TRP RETIREM	20,628	12/31/2024
57630G-18-5	MASSMUTUAL SELECT TRP RETIREM	20,628	12/31/2024
57630G-18-5	MASSMUTUAL SELECT TRP RETIREM	20,628	12/31/2024
57630G-18-5	MASSMUTUAL SELECT TRP RETIREM	20,628	12/31/2024
57630G-18-5	MASSMUTUAL SELECT TRP RETIREM	20,628	12/31/2024
57629H-35-0	MASSMUTUAL:CR B I	113,311	12/31/2024
57629H-35-0	MASSMUTUAL:CR B I	113,311	12/31/2024
57629H-35-0	MASSMUTUAL:CR B I	113,311	12/31/2024
57629H-35-0	MASSMUTUAL:CR B I	113,311	12/31/2024
57629H-35-0	MASSMUTUAL:CR B I	113,311	12/31/2024
552966-80-6	MFS INTERNATIONAL EQT R6	22,087,999	12/31/2024
552966-80-6	MFS INTERNATIONAL EQT R6	22,087,999	12/31/2024
552966-80-6	MFS INTERNATIONAL EQT R6	22,087,999	12/31/2024
552966-80-6	MFS INTERNATIONAL EQT R6	22,087,999	12/31/2024
552966-80-6	MFS INTERNATIONAL EQT R6	22,087,999	12/31/2024
704329-24-2	PAYDEN:EM MKT BD SI	11,673,580	12/31/2024
704329-24-2	PAYDEN:EM MKT BD SI	11,673,580	12/31/2024
704329-24-2	PAYDEN:EM MKT BD SI	11,673,580	12/31/2024
704329-24-2	PAYDEN:EM MKT BD SI	11,673,580	12/31/2024
704329-24-2	PAYDEN:EM MKT BD SI	11,673,580	12/31/2024
779562-20-6	T ROWE PRICE NH I	118,645	12/31/2024
779562-20-6	T ROWE PRICE NH I	118,645	12/31/2024
779562-20-6	T ROWE PRICE NH I	118,645	12/31/2024
779562-20-6	T ROWE PRICE NH I	118,645	12/31/2024
779562-20-6	T ROWE PRICE NH I	118,645	12/31/2024
922908-83-5	VANGUARD MD-CP I INST	289,258	12/31/2024
922908-83-5	VANGUARD MD-CP I INST	289,258	12/31/2024
922908-83-5	VANGUARD MD-CP I INST	289,258	12/31/2024
922908-83-5	VANGUARD MD-CP I INST	289,258	12/31/2024
922908-83-5	VANGUARD MD-CP I INST	289,258	12/31/2024
921908-87-7	VANGUARD RE IDX ADM	165,063	12/31/2024
921908-87-7	VANGUARD RE IDX ADM	165,063	12/31/2024
921908-87-7	VANGUARD RE IDX ADM	165,063	12/31/2024
921908-87-7	VANGUARD RE IDX ADM	165,063	12/31/2024
921908-87-7	VANGUARD RE IDX ADM	165,063	12/31/2024
922908-87-6	VANGUARD S-C ID INST	285,988	12/31/2024
922908-87-6	VANGUARD S-C ID INST	285,988	12/31/2024
922908-87-6	VANGUARD S-C ID INST	285,988	12/31/2024
922908-87-6	VANGUARD S-C ID INST	285,988	12/31/2024
922908-87-6	VANGUARD S-C ID INST	285,988	12/31/2024
969251-71-9	WM BLAIR:INTL LDRS I	169,948	12/31/2024
969251-71-9	WM BLAIR:INTL LDRS I	169,948	12/31/2024
969251-71-9	WM BLAIR:INTL LDRS I	169,948	12/31/2024
969251-71-9	WM BLAIR:INTL LDRS I	169,948	12/31/2024
969251-71-9	WM BLAIR:INTL LDRS I	169,948	12/31/2024

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
	Statement (Admitted) Value	Fair Value	Excess of Statement over Fair Value (-), or Fair Value over Statement (+)
31.1 Bonds	459,971,743	434,098,902	(25,872,841)
31.2 Preferred stocks	19,046,132	19,046,132	
31.3 Totals	479,017,875	453,145,034	(25,872,841)

GENERAL INTERROGATORIES

31.4 Describe the sources or methods utilized in determining the fair values:
PROVIDED BY RATING SOURCES UTILIZED BY THE CUSTODIAN, NORTHERN TRUST. PRICING SOURCES
INCLUDES IDC, ICE, S&P GLOBAL, JPM PRICING, IHS MARKIT, SIX FINANCIAL, NSCC, BLOOMBERG

32.1 Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?

Yes [] No [X]

32.2 If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's
pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?

Yes [] No []

32.3 If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing
source for purposes of disclosure of fair value for Schedule D:

33.1 Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been
followed?

Yes [] No [X]

33.2 If no, list exceptions:

34 By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security:

a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available.

b. Issuer or obligor is current on all contracted interest and principal payments.

c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.

Has the reporting entity self-designated 5GI securities?

Yes [] No [X]

35 By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security:

a. The security was either:

i. issued prior to January 1, 2018 (which is exempt from PLR filing requirements pursuant to the P&P Manual), or

ii. issued from January 1, 2018 to December 31, 2021 and subject to a confidentiality agreement executed prior to January 1, 2022 which confidentiality
agreement remains in force, for which an insurance company cannot provide a copy of a private letter rating rationale report to the SVO due to confidentiality
or other contractual reasons ("waived submission PLR securities").

b. The reporting entity is holding capital commensurate with the NAIC Designation and NAIC Designation Category reported for the security.

c. The NAIC Designation and NAIC Designation Category were derived from the credit rating assigned by an NAIC CRP in its legal capacity as an NRSRO
which is shown on a current private letter rating, dated during the financial statement year, held by the insurer and available for examination by state
insurance regulators.

d. Other than for waived submission PLR securities, defined above, on or after January 1, 2024 for any PLR securities issued on or after January 1, 2022,
if the reporting entity is not permitted to share this private credit rating or the private rating letter rationale report of the PL security with the SVO, it certifies
that it is reporting it as an NAIC 5.B GI and may not assign any other self-designation.

Has the reporting entity self-designated PLGI to securities, all of which meet the above requirement and as specified
in the P&P Manual?

Yes [] No [X]

36. By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund:

a. The shares were purchased prior to January 1, 2019.

b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.

c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior
to January 1, 2019.

d. The fund only or predominantly holds bonds in its portfolio.

e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP
in its legal capacity as an NRSRO.

f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed.

Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?

Yes [] No [X]

GENERAL INTERROGATORIES

37. By rolling/renewing short-term or cash-equivalent investments with continued reporting on Schedule DA, part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following:

a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date.

b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties.

c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review.

d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a - 37.c are reported as long-term investments.

Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria?

Yes ☐ No ☒ N/A ☐

38.1 Does the reporting entity directly hold cryptocurrencies?

Yes ☐ No ☒

38.2 If the response to 38.1 is yes, on what schedule are they reported?

39.1 Does the reporting entity directly or indirectly accept cryptocurrencies as payments for premiums on policies?

Yes ☐ No ☒

39.2 If the response to 39.1 is yes, are the cryptocurrencies held directly or are they immediately converted to U.S. dollars?

39.21 Held directly

Yes ☐ No ☒

39.22 Immediately converted to U.S. dollars

Yes ☐ No ☒

39.3 If the response to 38.1 or 39.1 is yes, list all cryptocurrencies accepted for payments of premiums or that are held directly.

1	2	3
Name of Cryptocurrency	Immediately Converted to USD, Directly Held, or Both	Accepted for Payment of Premiums

OTHER

40.1 Amount of payments to trade associations, service organizations and statistical or Rating Bureaus, if any?

\$ 183,377,262

40.2 List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to trade associations, service organizations and statistical or rating bureaus during the period covered by this statement.

1	2
Name	Amount Paid
BLUE CROSS BLUE SHIELD ASSOCIATION	\$ 830,361
	\$
	\$

41.1 Amount of payments for legal expenses, if any?

\$ 203,025,372

41.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal expenses during the period covered by this statement.

1	2
Name	Amount Paid
HOGAN LOVELLS US LLP	\$ 304,018
BLUE CROSS BLUE SHIELD ASSOCIATION	\$ 251,851
ROPES & GRAY LLP	\$ 207,350
PIERCE ATWOOD LLP	\$ 204,747
NELSON MULLINS RILEY & SCARBOROUGH, LLP	\$ 197,868

42.1 Amount of payments for expenditures in connection with matters before legislative bodies, officers or departments of government, if any?

\$ 20,311,787

42.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures in connection with matters before legislative bodies, officers or departments of government during the period covered by this statement.

1	2
Name	Amount Paid
STATE OF RHODE ISLAND	\$ 434,025
	\$
	\$

27.11

GENERAL INTERROGATORIES
PART 2 - HEALTH INTERROGATORIES

1.1 Does the reporting entity have any direct Medicare Supplement Insurance in force?

Yes [X] No []

1.2 If yes, indicate premium earned on U.S. business only.

\$ 59,564,143

1.3 What portion of Item (1.2) is not reported on the Medicare Supplement Insurance Experience Exhibit?

\$

1.31 Reason for excluding

1.4 Indicate amount of earned premium attributable to Canadian and/or Other Alien not included in Item (1.2) above.

\$

1.5 Indicate total incurred claims on all Medicare Supplement insurance.

\$ 48,609,503

1.6 Individual policies:

Most current three years:

1.61 Total premium earned

\$ 1,429,064

1.62 Total incurred claims

\$ 1,161,586

1.63 Number of covered lives

491

All years prior to most current three years:

1.64 Total premium earned

\$ 41,843,801

1.65 Total incurred claims

\$ 34,011,889

1.66 Number of covered lives

14,349

1.7 Group policies:

Most current three years:

1.71 Total premium earned

\$ 70,284

1.72 Total incurred claims

\$ 57,966

1.73 Number of covered lives

96

All years prior to most current three years:

1.74 Total premium earned

\$ 16,220,994

1.75 Total incurred claims

\$ 13,378,063

1.76 Number of covered lives

426

2. Health Test:

	1		2
	Current Year		Prior Year
2.1 Premium Numerator	\$ 2,212,944,959	\$	2,049,694,139
2.2 Premium Denominator	\$ 2,212,944,959	\$	2,049,694,139
2.3 Premium Ratio (2.1 / 2.2)	100.000		100.000
2.4 Reserve Numerator	\$ 349,357,033	\$	326,215,827
2.5 Reserve Denominator	\$ 344,031,034	\$	321,685,613
2.6 Reserve Ratio (2.4 / 2.5)	101.548		101.408

3.1 Has the reporting entity received any endowment or gift from contracting hospitals, physicians, dentists, or others that is agreed will be returned when, as and if the earnings of the reporting entity permits?

Yes [] No [X]

3.2 If yes, give particulars:

4.1 Have copies of all agreements stating the period and nature of hospitals', physicians', and dentists' care offered to subscribers and dependents been filed with the appropriate regulatory agency?

Yes [X] No []

4.2 If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these agreements include additional benefits offered?

Yes [] No [X]

5.1 Does the reporting entity have stop-loss reinsurance?

Yes [X] No []

5.2 If no, explain:

5.3 Maximum retained risk (see instructions)

5.31 Comprehensive Medical

\$

5.32 Medical Only

\$

5.33 Medicare Supplement

\$

5.34 Dental and vision

\$

5.35 Other Limited Benefit Plan

\$

5.36 Other

\$

6. Describe arrangement which the reporting entity may have to protect subscribers and their dependents against the risk of insolvency including hold harmless provisions, conversion privileges with other carriers, agreements with providers to continue rendering services, and any other agreements:
THE PLAN ESTABLISHES RATES WITH THE PROPER CONDUCT OF ITS BUSINESS WITH THE INTEREST OF THE PUBLIC. THE PLAN IS TO MAINTAIN SURPLUS IN EXCESS OF 200% OF RISK BASED CAPITAL AUTHORIZED CONTROL LEVEL THAT AMOUNTED TO \$142,299,836. AS A RESULT, NO REGULATORY ACTION WAS TRIGGERED. THE PLAN HAS HOLD HARMLESS PROVISIONS IN ITS CONTRACTS WITH PARTICIPATING HOSPITALS AND PROVIDERS.

GENERAL INTERROGATORIES
PART 2 - HEALTH INTERROGATORIES

7.1 Does the reporting entity set up its claim liability for provider services on a service date basis?

Yes ☒ No ☐

7.2 If no, give details:

8. Provide the following information regarding participating providers:

8.1 Number of providers at start of reporting year

8.2 Number of providers at end of reporting year

4,317

9.1 Does the reporting entity have business subject to premium rate guarantees?

Yes ☐ No ☒

9.2 If yes, direct premium earned:

9.21 Business with rate guarantees between 15-36 months

9.22 Business with rate guarantees over 36 months

10.1 Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its provider contracts?

Yes ☐ No ☒

10.2 If yes:

10.21 Maximum amount payable bonuses

10.22 Amount actually paid for year bonuses

10.23 Maximum amount payable withholds

10.24 Amount actually paid for year withholds

\$

\$

\$

\$

11.1 Is the reporting entity organized as:

11.12 A Medical Group/Staff Model,

11.13 An Individual Practice Association (IPA), or,

11.14 A Mixed Model (combination of above)?

Yes ☐ No ☒

Yes ☐ No ☒

Yes ☐ No ☒

11.2 Is the reporting entity subject to Statutory Minimum Capital and Surplus Requirements?

Yes ☐ No ☒

11.3 If yes, show the name of the state requiring such minimum capital and surplus:

11.4 If yes, show the amount required.

\$

11.5 Is this amount included as part of a contingency reserve in stockholder's equity?

Yes ☐ No ☒

11.6 If the amount is calculated, show the calculation:

12. List service areas in which reporting entity is licensed to operate:

1		
Name of Service Area		
Rhode Island		

13.1 Do you act as a custodian for health savings accounts?

Yes ☐ No ☒

13.2 If yes, please provide the amount of custodial funds held as of the reporting date.

\$

13.3 Do you act as an administrator for health savings accounts?

Yes ☐ No ☒

13.4 If yes, please provide the balance of the funds administered as of the reporting date.

\$

14.1 Are any of the captive affiliates reported on Schedule S, Part 3, authorized reinsurers?

Yes ☐ No ☐ N/A ☒

14.2 If the answer to 14.1 is yes, please provide the following:

1 Company Name	2 NAIC Company Code	3 Domiciliary Jurisdiction	4 Reserve Credit	Assets Supporting Reserve Credit		
				5 Letters of Credit	6 Trust Agreements	7 Other

15. Provide the following for individual ordinary life insurance* policies (U.S. business only) for the current year (prior to reinsurance assumed or ceded).

15.1 Direct Premium Written

15.2 Total Incurred Claims

15.3 Number of Covered Lives

\$

\$

*Ordinary Life Insurance Includes
Term (whether full underwriting, limited underwriting, jet issue, "short form app")
Whole Life (whether full underwriting, limited underwriting, jet issue, "short form app")
Variable Life (with or without secondary guarantee)
Universal Life (with or without secondary guarantee)
Variable Universal Life (with or without secondary guarantee)

28.1

GENERAL INTERROGATORIES
PART 2 - HEALTH INTERROGATORIES

16. Is the reporting entity licensed or chartered, registered, qualified, eligible or writing business in at least two states?

Yes [☐] No [☒]
- 16.1 If no, does the reporting entity assume reinsurance business that covers risks residing in at least one state other than the state of domicile of the reporting entity?

Yes [☐] No [☒]

FIVE – YEAR HISTORICAL DATA

	1	2	3	4	5
	2024	2023	2022	2021	2020
Balance Sheet (Pages 2 and 3)					
1. Total admitted assets (Page 2, Line 28)	1,017,621,413	1,025,794,353	922,703,337	924,260,302	862,104,146
2. Total liabilities (Page 3, Line 24)	680,449,900	586,245,856	513,748,754	489,567,441	446,289,912
3. Statutory minimum capital and surplus requirement	142,299,838	133,965,612	155,382,795	148,856,753	141,627,515
4. Total capital and surplus (Page 3, Line 33)	337,171,513	439,548,497	408,954,583	434,692,861	415,814,234
Income Statement (Page 4)					
5. Total revenues (Line 8)	2,212,944,959	2,045,132,082	1,883,598,404	1,795,520,104	1,707,243,198
6. Total medical and hospital expenses (Line 18)	2,010,791,255	1,825,926,990	1,631,116,035	1,542,709,739	1,403,371,707
7. Claims adjustment expenses (Line 20)	77,872,682	63,506,822	59,630,823	58,743,347	58,190,620
8. Total administrative expenses (Line 21)	224,069,300	172,654,392	181,846,685	183,427,950	207,567,850
9. Net underwriting gain (loss) (Line 24)	(113,248,278)	(25,956,122)	19,004,861	9,239,068	7,713,021
10. Net investment gain (loss) (Line 27)	16,887,982	9,516,964	7,258,198	17,509,110	7,857,917
11. Total other income (Lines 28 plus 29)	(18,658,096)	17,040,901	(5,219,669)	(13,580,656)	(9,407,830)
12. Net income or (loss) (Line 32)	(115,018,392)	601,743	21,043,390	13,167,522	42,421,212
Cash Flow (Page 6)					
13. Net cash from operations (Line 11)	(37,094,821)	41,859,713	(67,103,723)	24,572,232	118,444,567
Risk-Based Capital Analysis					
14. Total adjusted capital	337,171,513	439,548,497	408,954,583	434,692,861	415,814,234
15. Authorized control level risk-based capital	71,149,919	66,982,806	64,201,018	63,315,995	58,616,377
Enrollment (Exhibit 1)					
16. Total members at end of period (Column 5, Line 7)	388,681	388,506	385,941	384,423	383,138
17. Total members months (Column 6, Line 7)	4,659,193	4,251,422	4,607,876	4,632,706	4,615,572
Operating Percentage (Page 4)					
(Item divided by Page 4, sum of Lines 2, 3, and 5) x 100.0					
18. Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19. Total hospital and medical plus other non-health (Line 18 plus Line 19)	90.9	89.3	86.6	85.9	82.2
20. Cost containment expenses	1.8	1.6	1.5	1.6	1.5
21. Other claims adjustment expenses	1.7	1.7	1.6	1.7	1.9
22. Total underwriting deductions (Line 23)	105.1	101.3	99.0	99.5	99.5
23. Total underwriting gain (loss) (Line 24)	(5.1)	(1.3)	1.0	0.5	0.5
Unpaid Claims Analysis					
(U&I Exhibit, Part 2B)					
24. Total claims incurred for prior years (Line 17, Col. 5)	123,487,010	104,862,546	148,214,411	124,937,641	129,180,624
25. Estimated liability of unpaid claims-[prior year (Line 17, Col. 6)]	230,100,736	136,417,315	147,411,278	143,577,383	135,665,500
Investments In Parent, Subsidiaries and Affiliates					
26. Affiliated bonds (Sch. D Summary, Line 12, Col. 1)					
27. Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)					
28. Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)					
29. Affiliated short-term investments (subtotal included in Sch. DA Verification, Col. 5, Line 10)					
30. Affiliated mortgage loans on real estate					
31. All other affiliated		10,226,793		2,531,710	3,531,202
32. Total of above Lines 26 to 31		10,226,793		2,531,710	3,531,202
33. Total investment in parent included in Lines 26 to 31 above.					

NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure requirements of SSAP No. 3, Accounting Changes and Correction of Errors?

Yes [] No []

If no, please explain:

SCHEDULE T - PREMIUMS AND OTHER CONSIDERATIONS
Allocated by States and Territories

		1	Direct Business Only								
			2	3	4	5	6	7	8	9	10
States, Etc.		Active Status (a)	Accident & Health Premiums	Medicare Title XVIII	Medicaid Title XIX	CHIP Title XXI	Federal Employees Health Benefits Plan Premiums	Life & Annuity Premiums & Other Considerations	Property/ Casualty Premiums	Total Columns 2 Through 8	Deposit-Type Contracts
1. Alabama	AL	N									
2. Alaska	AK	N									
3. Arizona	AZ	N									
4. Arkansas	AR	N									
5. California	CA	N									
6. Colorado	CO	N									
7. Connecticut	CT	N									
8. Delaware	DE	N									
9. District of Columbia	DC	N									
10. Florida	FL	N									
11. Georgia	GA	N									
12. Hawaii	HI	N									
13. Idaho	ID	N									
14. Illinois	IL	N									
15. Indiana	IN	N									
16. Iowa	IA	N									
17. Kansas	KS	N									
18. Kentucky	KY	N									
19. Louisiana	LA	N									
20. Maine	ME	N									
21. Maryland	MD	N									
22. Massachusetts	MA	N									
23. Michigan	MI	N									
24. Minnesota	MN	N									
25. Mississippi	MS	N									
26. Missouri	MO	N									
27. Montana	MT	N									
28. Nebraska	NE	N									
29. Nevada	NV	N									
30. New Hampshire	NH	N									
31. New Jersey	NJ	N									
32. New Mexico	NM	N									
33. New York	NY	N									
34. North Carolina	NC	N									
35. North Dakota	ND	N									
36. Ohio	OH	N									
37. Oklahoma	OK	N									
38. Oregon	OR	N									
39. Pennsylvania	PA	N									
40. Rhode Island	RI	L	1,030,917.27	1,026,512,722			164,446,942			2,221,876,940	
41. South Carolina	SC	N									
42. South Dakota	SD	N									
43. Tennessee	TN	N									
44. Texas	TX	N									
45. Utah	UT	N									
46. Vermont	VT	N									
47. Virginia	VA	N									
48. Washington	WA	N									
49. West Virginia	WV	N									
50. Wisconsin	WI	N									
51. Wyoming	WY	N									
52. American Samoa	AS	N									
53. Guam	GU	N									
54. Puerto Rico	PR	N									
55. U.S. Virgin Islands	VI	N									
56. Northern Mariana Islands	MP	N									
57. Canada	CAN	N									
58. Aggregate other alien	OT	X X X									
59. Subtotal		X X X	1,030,917.27	1,026,512,722			164,446,942			2,221,876,940	
60. Reporting entity contributions for Employee Benefit Plans		X X X	2,971	931,458						934,429	
61. Totals (Direct Business)		X X X	1,030,920.24	1,027,444,180			164,446,942			2,222,811,369	

DETAILS OF WRITE-INS											
58001.		X X X									
58002.		X X X									
58003.		X X X									
58998.	Summary of remaining write-ins for Line 58 from overflow page	X X X									
58999.	Totals (Lines 58001 through 58003 plus 58998) (Line 58 above)	X X X									

- (a) Active Status Counts
1. L – Licensed or Chartered - Licensed insurance carrier or domiciled RRG

2. R - Registered - Non-domiciled RRGs

3. E – Eligible - Reporting entities eligible or approved to write surplus lines in the state

4. Q - Qualified - Qualified or accredited reinsurer

5. N – None of the above - Not allowed to write business in the state or none of the above codes apply
- 1


56

(b) Explanation of basis of allocation of premiums by states, etc.

ALL PREMIUMS ARE ALLOCATED TO RHODE ISLAND

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART



OVERFLOW PAGE FOR WRITE-INS

Page 2 - Continuation

ASSETS

	Current Year			Prior Year
	1	2	3	4
REMAINING WRITE-INS AGGREGATED AT LINE 25 FOR OTHER THAN INVESTED ASSETS	Assets	Nonadmitted Assets	Net Admitted Assets (Cols. 1 - 2)	Net Admitted Assets
2504. HISTORICAL TAX CREDITS	5,948,250		5,948,250	1,640,000
2505. LEASEHOLD IMPROVEMENTS	2,275,425	2,275,425		
2506. LOAN & INTEREST RECEIVABLE	210,719	210,719		
2507. COLLATERAL FUND HOME & HOST	198,284		198,284	212,777
2597. Totals (Lines 2504 through 2596) (Page 2, Line 2598)	8,632,678	2,486,144	6,146,534	1,852,777

OVERFLOW PAGE FOR WRITE-INS

Page 3 - Continuation

LIABILITIES, CAPITAL AND SURPLUS

	Current Year			Prior Year
	1 Covered	2 Uncovered	3 Total	4 Total
WRITE-INS AGGREGATED AT LINE 23 FOR OTHER LIABILITIES				
2304. UNFUNDED ACCUMULATED BENEFIT OBLIGATION	(1,451,173)		(1,451,173)	(806,848)
2397. Totals (Lines 2304 through 2396) (Page 3, Line 23)	(1,451,173)		(1,451,173)	(806,848)

OVERFLOW PAGE FOR WRITE-INS

Page 4 - Continuation

STATEMENT OF REVENUE AND EXPENSES

WRITE-INS AGGREGATED AT LINE 29 FOR STATEMENT OF REVENUE AND EXPENSES	Current Year		Prior Year
	1 Uncovered	2 Total	3 Total
2904. OTHER INCOME (NON CORE BUSINESS)			20,000,000
2905. INTEREST EXPENSE IRS		(6,528)	(174,225)
2906. HEALTH INFORMATION EXCHANGE		(1,049,749)	(1,086,504)
2907. BANK SERVICE CHARGES		(2,294,051)	(1,287,923)
2908. OTHER EXPENSE - SETTLEMENT COSTS		(16,251,420)	(1,535,186)
2997. Totals (Lines 2901 through 2996) (Page 4, Line 2998)		(19,601,748)	15,916,162

OVERFLOW PAGE FOR WRITE-INS

Page 13 - Continuation

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D – AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

WRITE-INS AGGREGATED AT LINE 05 FOR UNDERWRITING AND INVESTMENT EXHIBIT	1 Total	Comprehensive (Hospital & Medical)		4 Medicare Supplement	5 Vision Only	6 Dental Only	7 Federal Employees Health Benefits Plan	8 Title XVIII Medicare	9 Title XIX Medicaid	10 Credit A&H	11 Disability Income	12 Long-Term Care	13 Other
		2 Individual	3 Group										
0597. Totals (Lines 0501 through 0596) (Page 13, Line 0598)													
WRITE-INS AGGREGATED AT LINE 11 FOR UNDERWRITING AND INVESTMENT EXHIBIT	1 Total	Comprehensive (Hospital & Medical)		4 Medicare Supplement	5 Vision Only	6 Dental Only	7 Federal Employees Health Benefits Plan	8 Title XVIII Medicare	9 Title XIX Medicaid	10 Credit A&H	11 Disability Income	12 Long-Term Care	13 Other
		2 Individual	3 Group										
1197. Totals (Lines 1101 through 1196) (Page 13, Line 1198)													

OVERFLOW PAGE FOR WRITE-INS

Page 14 - Continuation

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 – ANALYSIS OF EXPENSES

	Claim Adjustment Expenses		3	4	5
	1	2			
WRITE-INS AGGREGATED AT LINE 25 FOR UNDERWRITING AND INVESTMENT EXHIBIT	Cost Containment Expenses	Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
2504. AGENCY & PORTFOLIO MANAGEMENT FEES				1,428,044	1,428,044
2505. CLAIMS HANDLING EXPENSE		282,400			282,400
2506. BLUECARD ADMIN FEE INCOME	(3,315,610)	(3,204,351)			(6,519,961)
2597. Totals (Lines 2501 through 2596) (Page 14, Line 2598)	(3,315,610)	(2,921,951)		1,428,044	(4,809,517)

OVERFLOW PAGE FOR WRITE-INS

Page 16 - Continuation

EXHIBIT OF NONADMITTED ASSETS

	1	2	3
	Current Year	Prior Year	Change in Total
	Total	Total	Nonadmitted Assets
DETAILS OF WRITE-IN LINES FOR	Nonadmitted	Nonadmitted Assets	(Col. 2 - Col. 1)
OTHER THAN INVESTED ASSETS AT LINE 25	Assets		
2504. LOAN & INTEREST RECEIVABLE	210,719	245,339	34,620
2505. FEP UNPAID CLAIMS			
2506. HISTORICAL TAX CREDITS			
2507. COLLATERAL FUND HOME & HOST			
2597. Totals (Lines 2504 through 2596) (Page 16, Line 2598)	210,719	245,339	34,620

OVERFLOW PAGE FOR WRITE-INS

Page 17 - Continuation

EXHIBIT 1 – ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

	Total Members at End of					6 Current Year Member Months
	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	
WRITE-INS AGGREGATED AT LINE 06 FOR EXHIBIT 1						
0604. VISION ONLY	20,026	20,271	20,628	19,958	20,127	241,882
0605. MEDICARE PRESCRIPTION DRUG PLAN	8,989	8,829	8,805	8,760	8,740	105,551
0697. Totals (Lines 0601 through 0697) (Page 17, Line 06)	29,015	29,100	29,433	28,718	28,867	347,433